TITLE OF THE INVENTION

CLONED GENES ENCODING IG-CD4 FUSION PROTEINS AND THE USE THEREOF

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of U.S. Application Serial No. 07/147,351 filed January 22, 1988.

FIELD OF THE INVENTION

The invention is in the field of recombinant genetics.

BACKGROUND OF THE INVENTION

The human and simian immunodeficiency viruses HIV and SIV are the causative agents of Acquired Immune Deficiency Syndrome (AIDS) and Simian Immunodeficiency Syndrome (SIDS), respectively. See Curren, J. _________ Science 329:1359-1357 (1985); Weiss, R. et al .. Nature

324:572-575 (1986). The HIV virus contains an envelope glycoprotein, gpl20 which binds to the CD4 protein present on the surface of helper T lymphocytes, macrophages and other cells. Dalgleish et al . Nature, 31£:763 (1984). After the gpl20 binds to CD4, virus entry is facili¬ tated by an envelope-mediated fusion of the viral target cell mem¬ branes.

During the course of infection, the host ^" organism develops antibodies against viral proteins, including the major envelope gTycoproteins gpl20 and gp41. Despite this humoral immunity, the disease progresses, resulting in a lethal immunosuppression charac¬ terized by multiple opportunistic infections, parasitemia, dementia and death. The failure of host anti-viral antibodies to arrest the progression of the disease represents one of the most vexing and alarming aspects of the infection, and augurs poorly for vaccination efforts based upon conventional approaches.

Two factors may play a role in the inefficacy of the humoral response to immunodeficiency viruses. First, like other RNA viruses (and like retroviruses in particular), the immunodeficiency viruses show a high mutation rate which allows antigenic variation to progress at a high rate in response to host immune surveillance. Second, the envelope glycoproteins themselves are heavily glycosylated molecules presenting few epitopes suitable for high affinity antibody binding. The poorly antigenic, "moving" target which the viral envelope presents, allows the host little opportunity for restricting viral infection by specific antibody production.

Cells infected by the HIV virus express the gpl20 glycoprotein on their surface. Gpl20 mediates fusion events among CD4 ⁺ cells via a reaction similar to that by which the virus enters the uninfected cell, leading to the formation of short-lived multinucleated giant cells. Syncytium formation is dependent on a direct interaction of the gpl20 envelope glycoprotein with the CD4 protein. Dalgleish et al.. supra. Klatzmann, D. et al.. Nature 112:763 (1984); McDougal, J.S. et al. Science. 231:382 (1986); Sodroski, J. et al .. Nature. 322:470 (1986); Lifson, J.D. et al .. Nature. 323:725 (1986); Sodroski, J. et al.. Nature. 321:412 (1986).

The CD4 protein consists of a 370 amino acid extracellular region containing four immunoglobulin-like domains, a membrane spanning domain, and a charged intracellular region of 40 a ino acid residues.

Maddon, P. et al.. Cell 42:93 (1985); Clark, S. et al .. Proc. Nat! . Acad. Sci. (USA) 84:1649 (1987).

Evidence that CD4-gpl20 binding is responsible for viral infec¬ tion of cells bearing the CD4 antigen includes the finding that a specific complex is formed between gpl20 and CD4. McDougal et al.. supra. Other workers have shown that cell lines, which were non- infective for HIV, were converted to infectable cell lines following transfection and expression of the human CD4 cDNA gene. Maddon et al.. Cell 47:333-348 (1986).

In contrast to the majority of antibody-envelope interactions, the receptor-envelope interaction is characterized by a high affinity (K _a = 10 ⁸ l/mole) immutable association. Moreover, the affinity of the virus for CD4 is at least 3 orders of magnitude higher than the affinity of CD4 for its putative endogenous ligand, the MHC class II antigens. Indeed, to date, a specific physical association between monomeric CD4 and class II antigens has not been demonstrated.

In response to bacterial or other particle infection, the host organism usually produces serum antibodies that bind to specific proteins or carbohydrates on the bacterial or particle surface, coating the bacteria. This antibody coat on the bacterium or other particle stimulates cytolysis by Fc-receptor-bearing lymphoid cells by antibody-dependent cellular toxicity (ADCC). Other serum proteins, collectively called complement (C), bind to antibody-coated targets, and also can coat foreign particles nonspecifically. They cause cell death by lysis, or stimulate ingestion by binding to specific receptors on the acrophage called complement receptors. See Darnell J. et al .. in Molecular Cell Biology. Scientific American Books, pp. 641 and 1087 (1986).

The most effective complement activating classes of human Ig are IgM and IgGl. The complement system consists of 14 proteins that, acting in order, cause lysis of cells. Nearly all of the C proteins exist in normal serum as inactive precursors. When activated, some

become highly specific proteolytic enzymes whose substrate is the next protein in a sequential chain reaction.

The entire C sequence can be triggered by either of two initia¬ tion pathways. In one (the classic pathway), Ab-Ag complexes bind and activate Cl, C4 and C2 to form a C3-splitting enzyme. In the second pathway, polysaccharides commonly on the surface of many bacteria and fungi bind with trace amounts of a C3 fragment and then with two other proteins (factor B and properdin) to form another C3-splitting enzyme. Once C3 is split by either pathway, the way is open for the remaining sequence of steps which lead to cell lysis. See Davis, B.D., et al ., In Microbiology. 3rd ed., Harper and Row, Philadelphia, PA, pp. 452- 466 (1980).

A number of workers have disclosed methods for preparing hybrid proteins. For example, Murphy, United States Patent 4,675,382 (1987), discloses the use of recombinant DNA techniques to make hybrid protein molecules by forming the desired fused gene coding for a hybrid protein of diptheria toxin and a polypeptide ligand such as a hormone, followed by expression of the fused gene.

Many workers have prepared monoclonal antibodies (Mabs) by recombinant DNA techniques. Monoclonal antibodies are highly specific well-characterized molecules in both primary and tertiary structure. They have been widely used for in vitro immunochemical characteriza¬ tion and quantitation of antigens. Genes for heavy and light chains have been introduced into appropriate hosts and expressed, followed by reaggregation of the individual chains into functional antibody molecules (see, for example, Munro, Nature 312:597 (1984); Morrison, S.L., Science 229:1202 ^' (1985); Oi et al.. Biotechnioues 4:214 (1986); Wood et al .. Nature 314:446-449 (1985)). Light- and heavy-chain variable regions have been cloned and expressed in foreign hosts wherein they maintained their binding ability (Moore et al .. European Patent Application 0088994 (published September 21, 1983)).

Chimeric or hybrid antibodies have also been prepared by recom¬ binant DNA techniques. Oi and Morrison, Biotechniαues 4:214 (1986)

describe a strategy for producing such chimeric antibodies which include a chimeric human IgG anti-leu3 antibody.

Gascoigne, N.R.J., et al.. Proc. Natl . Acad. Sci. (USA) 84:2936- 2940 (1987) disclose the preparation of a chimeric gene construct containing a T-cell receptor α-chain variable (V) domain and the constant (C) region coding sequence of an immunoglobulin γ2a molecule. Cells transfected with the chimeric gene synthesize a protein product that expresses i munoglobulin and T-cell receptor antigenic determinants as well as protein A binding sites. This protein associates with a normal λ chain to form an apparently normal tetrameric (H2 2, where H=heavy and L=light) immunoglobulin molecule that is secreted.

Sharon, J., et al.. Nature 309:54 (1984), disclose construction of a chimeric gene encoding the variable (V) region of a mouse heavy chain specific for the hapten azophenylarsonate and the constant (C) region of a mouse kappa light chain (VμC _κ ). This gene was introduced into a mouse myeloma cell line. The chimeric gene was expressed to give a protein which associated with light chains secreted from the myeloma cell line to give an antibody molecule specific for azophenylarsonate.

Morrison, Science 229:1202 (1985), discloses that variable light- or variable heavy-chain regions can be attached to a non-Ig sequence to create fusion proteins. This article states that the potential uses for the fusion proteins are three: (1) to attach antibody specifically to enzymes for use in assays; (2) to isolate non-Ig proteins by antigen columns; and (3) to specifically deliver toxic agents.

Recent techniques for the stable introduction of immunoglobulin genes into myeloma cells (Banerji, J., et al .. Cell 33:729-740 (1983); Potter, H., et al .. Proc. Natl. Acad. Sci. (USA) 81:7161-7165 (1984)), coupled with detailed structural information, have permitted the use of in vitro DNA methods such as mutagenesis, to generate recombinant antibodies possessing novel properties.

PCT Application W087/02671 discloses methods for producing genetically engineered antibodies of desired variable region specifi¬ city and constant region properties through gene cloning and expres¬ sion of light and heavy chains. The mRNA from cloned hybridoma B cell lines which produce monoclonal antibodies of desired specificity is isolated for cDNA cloning. The generation of light and heavy chain coding sequences is accomplished by excising the cloned variable regions and ligating them to light or heavy chain module vectors. This gives cDNA sequences which code for immunoglobulin chains. The lack of introns allows these cDNA sequences to be expressed in prokaryotic hosts, such as bacteria, or in lower eukaryotic hosts, such as yeast.

The generation of chimeric antibodies in which the antigen- binding portion of the immunoglobulin is fused to other moieties has been demonstrated. Examples of non-immunoglobulin genes fused to antibodies include Staphylococcus aureus nuclease, the mouse oncogene c-myc, and the Klenow fragment of E. coli DNA polymerase I (Neuberger, M.S., et al.. Nature 312:604τ612 (1984); Neuberger, M.S., Trends in Biochemical Science. 347-349 (1985)). European Patent Application 120,694 discloses the genetic engineering of the variable and constant regions of an immunoglobulin molecule that is expressed in E. coli host cells. It is further disclosed that the immunoglobulin molecule may be synthesized by a host cell with another peptide moiety attached to one of the constant domains. Such peptide moieties are described as either cytotoxic or enzymatic. The application and the examples describe the use of a lambda-like chain derived from a monoclonal antibody which binds to 4-hydroxy-3-nitrophenyl (NP) haptens.

European Patent Application 125,023 relates to the use of recombinant DNA techniques to produce immunoglobul n molecules that are chimeric or otherwise modified. One of the uses described for these immunoglobulin molecules is for whole-body diagnosis and treatment by injection of the antibodies directed to specific target tissues. The presence of the disease can be determined by attaching a

suitable label to the antibodies, or the diseased tissue can be attacked by carrying a suitable drug with the antibodies. The application describes antibodies engineered to aid the specific delivery of an agent as "altered antibodies."

PCT Application W083/101533 describes chimeric antibodies wherein the variable region of an immunoglobulin molecule is linked to a portion of a second protein which may comprise the active portion of an enzyme.

Boulianne et al .. Nature 312:643 (1984) constructed an immuno¬ globulin gene in which the DNA segments that encode mouse variable regions specific for the hapten trinitrophenol (TNP) are joined to segments that encode human mu and kappa regions. These chimeric genes were expressed to give functional TNP-binding chimeric IgM.

Morrison et al .. P.N.A.S. (USA) 81:6851 (1984), disclose a chimeric molecule utilizing the heavy-chain variable region exons of an anti-phosphoryl choline myeloma protein G, which were joined to the exons of either human kappa light-chain gene. The genes were trans- fected into mouse myeloma cell lines, generating transformed cells, that produced chimeric mouse-human IgG with antigen-binding function.

Despite the progress that has been achieved on determining the mechanism of HIV infection, a need continues to exist for methods of treating HIV viral infections.

SUMMARY OF THE INVENTION

The invention relates to a gene comprising a DNA sequence which encodes a fusion protein comprising 1) CD4, or a fragment thereof which binds to HIV gpl20, and 2) an immunoglobulin light or heavy chain; wherein said CD4 or HIV gpl20-binding fragment thereof replaces the variable region of the light or heavy immunoglobulin chain.

The invention also relates to vectors containing the gene of the invention and hosts transformed with the vectors.

The invention also relates to a method of producing a fusion protein comprising CD4, or fragment thereof which binds to HIV gpl20, and an immunoglobulin light or heavy chain, wherein the variable region of the immunoglobulin light or heavy chain has been substituted with CD4, or HIV gpl20-binding fragment thereof, which comprises: cultivating in a nutrient medium under protein produc¬ ing conditions, a host strain transformed with the vector containing the gene of the invention, said vector further comprising expression signals which are recognized by said host strain and direct expression of said fusion protein, and recovering the fusion protein so produced. The invention also relates to a fusion protein comprising CD4, or fragment thereof which is capable of binding to HIV gpl20, fused at the C-terminus to a second protein which comprises an immunoglobulin light or heavy chain, wherein the variable region of said light or heavy chain is substituted with CD4 or a HIV gpl20 binding fragment thereof.

The invention also relates to an immunoglobulin-like molecule comprising the fusion protein of the invention together with an immunoglobulin light or heavy-chain, wherein said immunoglobulin like molecule binds HIV gpl20.

The IgGl fusion proteins and immunoglobulin-like molecules may be useful for both complement-mediated and cell-mediated (ADCC) immunity, while the IgM fusion proteins are useful principally through comple¬ ment-mediated immunity.

The invention also relates to a complex between the fusion proteins and immunoglobulin-like molecule of the invention and HIV gpl20.

The invention also relates to a method for treating HIV or SIV infections comprising administering the fusion protein or immunoglobu¬ lin-like molecule of the invention to an animal.

The invention further relates to a method for detecting HIV gpl20 in a sample comprising contacting a sample suspected of containing HIV

or gpl20 with the fusion protein or immunoglobulin-like molecule of the invention, and detecting whether a complex has formed.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The invention is directed to a protein gene which comprises

1) a DNA sequence which codes for CD4, or fragment thereof which binds to HIV gpl20, fused to

2) a DNA sequence which encodes an immunoglobulin heavy chain.

Preferably, the antibody has effector function.

The invention is also directed to a protein gene which comprises

1) a DNA sequence which codes for CD4, or fragment thereof which binds to HIV gpl20, fused to

2) a DNA sequence which encodes an immunoglobulin light chain; wherein said sequence which codes for CD4, or HIV gpl20-binding fragment thereof, replaces the variable region of the light immunoglobulin chain.

The invention is also directed to the expression of these novel fusion proteins in transformed hosts and the use thereof to treat and diagnose HIV infections. In particular, the invention relates to expressing said genes in mammalian hosts which express complementary light or heavy chain immunoglobulins to give immunoglobulin-like molecules which have antibody effector function and also bind to HIV or SIV gpl20.

The term "antibody effector function" as used herein denotes the ability to fix complement or to activate ADCC.

The fusion proteins and immunoglobulin-like molecules may be administered to an animal for the purpose of treating HIV or SIV infections. By the terms "HIV infections" is intended the condition of having AIDS, AIDS related complex (ARC) or where an animal harbors the AIDS virus, but does not exhibit the clinical symptoms of AIDS or

ARC. By the terms "SIV infections" is intended the condition of being infected with simian immunodeficiency virus.

By the term "animal" is intended all animals which may derive benefit from the administration of the fusion proteins and immuno¬ globulin-like molecules of the invention. Foremost among such -animals are humans, however, the invention is not intended to be so limited.

By the term "fusion protein" is intended a fused protein comprising CD4, or fragment thereof which is capable of binding to gpl20, linked at its C-terminus to an immunoglobulin chain wherein a portion of the N-terminus of the immunoglobulin is replaced with CD4. In general, that portion of immunoglobulin which is deleted is the variable region. The fusion proteins of the invention may also comprise immunoglobulins where more than just the variable region has been deleted and replaced with CD4 or HIV gpl20 binding fragment thereof. For example, the V^ and CHI regions of an immunoglobulin chain may be deleted. Preferably, any amount of the N-terminus of the immunoglobulin heavy chain can be deleted as long as the remaining fragment has antibody effector function. The minimum sequence required for binding complement encompasses domains CH2 and CH3. Joining of Fc portions by the hinge region is advantageous for increasing the efficiency of complement binding.

The CD4 portion of the fusion protein may comprise the complete CD4 sequence, the 370 amino acid extracellular region and the membrane spanning domain, or the extracellular region. The fusion protein may comprise fragments of the extracellular region obtained by cutting the DNA sequence which encodes CD4 at the BspMl site at position 514 or the PvuII site at position 629 (see Table 1) to give nucleotide sequences which encode CD4 fragments which retain binding to gpl20. In general, any fragment of CD4 may be used as long as it retains binding to gpl20.

Where the fusion protein comprises an immunoglobulin light chain, it is necessary that no more of the Ig chain be deleted than is necessary to form a stable complex with a heavy chain Ig. In particu-

lar, the cysteine residues necessary for disulfide bond formation must be preserved on both the heavy and light chain moieties.

When expressed in a host, e.g., a mammalian cell, the fusion protein may associate with other light or heavy Ig chains secreted by the cell to give a functioning immunoglobulin-like molecule which is capable of binding to gpl20. The gpl20 may be in solution, expressed on the surface of infected cells, or may be present on the surface of the HIV virus itself. Alternatively, the fusion protein may be expressed in a mammalian cell which does not secrete other light or heavy Ig chains. When expressed under these conditions, the fusion protein may form a homodimer.

Genomic or CDNA sequences may be used in the practice of the invention. Genomic sequences are expressed efficiently in myeloma cells, since they contain native promoter structures.

The constant regions of the antibody cloned and used in the chimeric immunoglobulin-like molecule may be derived from any mam¬ malian source. The constant regions may be complement binding or ADCC active. However, preliminary work (see Examples) indicates that the fusion proteins of the invention may mediate HIV or SIV infected cell death by an ADCC or complement-independent mechanism. The constant regions may be derived from any appropriate isotype, including IgGl, IgG3, or IgM.

The joining of various DNA fragments, is performed in accordance with conventional techniques, employing blunt-ended or staggered-ended termini for ligation, restriction enzyme digestion to provide appro¬ priate termini, filling in of cohesive ends as appropriate, alkali and phosphatase treatment to avoid undesirable joining, and ligation with appropriate ligases. The genetic construct may optionally encode a leader sequence to allow efficient expression of the fusion protein. For example, the leader sequence utilized by Maddon __________ Cell

42:93-104 (1985) for the expression of CD4 may be used.

For cDNA, the cDNA may be cloned and the resulting clone screen¬ ed, for example, by use of a complementary probe or by assay for

expressed CD4 using an antibody as disclosed by Dalgleish et al .. Nature 312:763-766 (1984); Klatzmann et al.. Immunol. Today 7:291-297

(1986); McDougal et al .. J. Immunol. 135:3151-3162 (1985); and McDougal, J. et al.. J. Immunol. 137:2937-2944 (1986).

To express the fusion hybrid protein, transcriptional and translational signals recognized by an appropriate host element are necessary. Eukaryotic hosts which may be used include mammalian cells capable of culture in vitro, particularly leukocytes, more particu¬ larly myeloma cells or other transformed or oncogenic lymphocytes, e.g., EBV-transformed cells. Alternatively, non-mammalian cells may be employed, such as bacteria, fungi, e.g., yeast, filamentous fungi, or the like.

Preferred hosts for fusion protein production are mammalian cells, grown in vitro in tissue culture or in vivo in animals. Mammalian cells provide post translational modification to immuno¬ globulin protein molecules which provide for correct folding and glycosylation of appropriate sites. Mammalian cells which may be useful as hosts include cells of fibroblast origins such as VERO or CH0-K1 or cells of lymphoid origin, such as the hybridoma SP2/0-AG14 or the myeloma P3x63Sgh, and their derivatives. For the purpose of preparing an immunoglobulin-like molecule, a plasmid containing a gene which encodes a heavy chain immunoglobulin, wherein the variable region has been replaced with CD4 or fragment thereof which binds to gpl20, may be introduced, for example, into J558L myeloma cells, a mouse plasmacytoma expressing the lambda-1 light chain but which does not express a heavy chain (see Oi et al .. P.N.A.S. (USA) 80:825-829 (1983)). Other preferred hosts include COS cells, BHK cells and hepatoma cells.

The constructs may be joined together to form a single DNA segment or may be maintained as separate segments, by themselves or in conjunction with vectors.

Where the fusion protein is not glycosylated, any host may be used to express the protein which is compatible with replicon and control sequences in the expression plasmid. In general, vectors containing replicon and control sequences are derived from species compatible with a host cell are used in connection with the host. The vector ordinarily carries a replicon site, as well as specific genes which are capable of providing phenotypic selection in transformed cells. The expression of the fusion protein can also be placed under control with other regulatory sequences which may be homologous to the organism in its untransformed state. For example, lactose-dependent E. coli chromosomal DNA comprises a lactose or lac operon which mediates lactose utilization by elaborating the enzyme beta-galacto- sidase. The lac control elements may be obtained from bacterial phage lambda placδ, which is infective for E. coli. The lac promoter- operator system can be induced by IPTG.

Other promoters/operator systems or portions thereof can be employed as well. For example, colicin El, galactose, alkaline phosphatase, tryptophan, xylose, tax, and the like can be used.

For mammalian hosts, several possible vector systems are avail¬ able for expression. One class of vectors utilize DNA elements which are derived from animal viruses such as bovine papilloma virus, polyoma virus, adenovirus,. vaccinia virus, baculovirus, retroviruses (RSV, MMTV or MOMLV), or SV40 virus. Cells which have stably inte¬ grated the DNA into their chromosomes may be selected by introducing one or more markers which allow selection of transfected host cells. The marker may provide for prototropy to an auxotrophic host, biocide resistance, e.g., antibiotics, or heavy metals such as copper or the like. The selectable marker gene can be either directly linked to the DNA sequences to be expressed, or introduced into the same cell by cotransformation. Additional elements may also be needed for optimal synthesis of mRNA. These elements may include splice signals, as well as transcriptional promoters, enhancers, and termination signals. The

cDNA expression vectors incorporating such elements includes those described by Okayama, H., Mol . Cel . Bio!.. 3:280 (1983) and others.

Once the vector or DNA sequence containing the constructs has been prepared for expression, the DNA constructs may be introduced to an appropriate host. Various techniques may be employed, such as protoplast fusion, calcium phosphate precipitation, electroporation or other conventional techniques. After the fusion, the cells are grown in media and screened for the appropriate activity. Expression of the gene(s) results in production of the fusion protein. This expressed fusion protein may then be subject to further assembly to form the immunoglobulin-Tike molecule.

The host cells for immunoglobulin production may be immortalized cells, primarily myeloma or lymphoma cells. These cells may be grown in appropriate nutrient medium in culture flasks or injected into a synergistic host, e.g., mouse or a rat, or immunodeficient host or host site, e.g., nude mouse or hamster pouch. In particular, the cells may be introduced into the abdominal cavity of an animal to allow production of ascites fluid which contains the immunoglobulin- like molecule. Alternatively, the cells may be injected subcutane- ously and the chimeric antibody is harvested from the blood of the host. The cells may be used in the same manner as hybridoma cells. See Diamond et al .. N. Eng. J. Med. 304:1344 (1981), and Kennatt, McKearn and Bechtol (Eds.), Monoclonal Antibodies: Hvbridomas: -- A New Dimension in Biologic Analysis. Plenum, 1980.

The fusion proteins and immunoglobulin-like molecules of the invention may be isolated and purified in accordance with conventional conditions, such as extraction, precipitation, chromatography, affinity chromatography, electrophoresis or the like. For example, the IgGl fusion proteins may be purified by passing a solution through a column which contains immobilized protein A or protein G which selectively binds the Fc portion of the fusion protein. See, for example, Reis, K.J., et al.. J. Immunol. 132:3098-3102 (1984); PCT Application, Publication No. W087/00329. The chimeric antibody may

the be eluted by treatment with a chaotropic salt or by elution with aqueous acetic acid (1 M).

Alternatively the fusion proteins may be purified on anti-CD4 antibody columns, or on anti-immunoglobulin antibody columns.

In one embodiment of the invention, cDNA sequences which encode CD4, or a fragment thereof which binds gpl20, may be ligated into an expression plasmid which codes for an antibody wherein the variable region of the gene has been deleted. Methods for the preparation of genes which encode the heavy or light chain constant regions of immunoglobulins are taught, for example, by Robinson, R. et al., PCT Application, Publication No. W087-02671.

Preferred immunoglobulin-like molecules which contain CD4, or fragments thereof, contain the constant region of an IgM, IgGl or IgG3 antibody which binds complement at the Fc region.

The fusion protein and immunoglobulin-like molecules of the invention may be used for the treatment of HIV viral infections. The fusion protein complexes to gpl20 which is expressed on infected cells. Although the inventor is not bound by a particular theory, it appears that the Fc portion of the hybrid fusion protein may bind with complement, which mediates destruction of the cell. In this manner, infected cells are destroyed so that additional viral particle production is stopped.

For the purpose of treating HIV infections, the fusion protein or immunoglobulin-like molecule of the invention may additionally contain a radiolabel or therapeutic agent which enhances destruction of the HIV particle or HIV-infected cell.

Examples of r ^' adioisotopes which can be bound to the fusion protein or immunoglobulin-like molecule of the invention for use in HIV-therapy are ¹²⁵ I, ¹³¹ I, ⁹⁰ Y, ⁶⁷ Cu, ²¹⁷ Bi, ²¹¹ At, ²¹² Pb, ⁴⁷ Sc, and Optionally, a label such as boron can be used which emits α and β particles upon bombardment with neutron radiation.

For in vivo diagnosis radionucleotides may be bound to the fusion protein or immunoglobulin-like molecule of the invention either directly or by using an intermediary functional group. An inter¬ mediary group which is often used to bind radioisotopes, which exist as metallic cations, to antibodies is diethylenetriaminepentaacetic

« acid (DTPA). Typical examples of metallic cations which are bound in this manner are ^99m Tc ¹²³ I, In, ¹³¹ I, ⁹⁷ Ru, ⁶⁷ Cu, ⁵⁷ Ga, and ⁶⁸ Ga.

Moreover, the fusion protein and immunoglobulin-like molecule of the invention may be tagged with an NMR imaging agent which include paramagnetic atoms. The use of an NMR imaging agent allows the in vivo diagnosis of the presence of and the extent of HIV infection within a patient using NMR techniques. Elements which are particu¬ larly useful in this manner are ^ Gd, ⁵ ^Mn, * ⁵² Dy, ⁵² Cr, and 56p _e#

Therapeutic agents may include, for example, bacterial toxins such as diphtheria toxin, or ricin. Methods for producing fusion proteins comprising fragment A of diphtheria toxin are taught in U.S. Patent 4,675,382 (1987). Diphtheria toxin contains two polypeptide chains. The B chain binds the toxin to a receptor on a cell surface. The A chain actually enters the cytoplasm and inhibits protein synthesis by inactivating elongation factor 2, the factor that translocates ribosomes along mRNA concomitant with hydrolysis of ETP. See Darnell, J., et al ., in Molecular Cell Biology, Scientific American Books, Inc., page 662 (1986). Alternatively, a fusion protein comprising ricin, a toxic lectin, may be prepared.

Introduction of the chimeric molecules by gene therapy may also be contemplated, for example, using retroviruses or other means to introduce the genetic material encoding the fusion proteins into suitable target tissues. In this embodiment, the target tissues having the cloned genes of the invention may then produce the fusion protein in vivo.

The dose ranges for the administration of the fusion protein or immunoglobulin-like molecule of the invention are those which are

large enough to produce the desired effect whereby the symptoms of HIV or SIV infection are ameliorated. The dosage should not be so large as to cause adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like. Generally, the dosage will vary with the age, condition, sex and extent of ^" disease in the patient, counterindications, if any, immune tolerance and other such variables, to be adjusted by the individual physician. Dosage can vary from .01 g/kg to 50 mg/kg, preferably 0.1 mg/kg to 1.0 mg/kg, of the immuno¬ globulin-like molecule in one or more administrations daily, for one or several days. The immunoglobulin-like molecule can be administered parenterally by injection or by gradual perfusion over time. They can be administered intravenously, intraperitoneally, intramuscularly, or subcutaneously.

Preparations for parenteral administration include sterile or aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueoύs solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alco¬ holic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles- include fluid and nutrient replenishers, electrolyte replenishes, such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, antimicrobials, anti- oxidants, chelating agents, inert gases and the like. See, generally, Remington's Pharmaceutical Science, 16th Ed., Mack Eds., 1980.

The invention also relates to a method for preparing a medicament or pharmaceutical composition comprising the components of the invention, the medicament being used for therapy of HIV or SIV infection in animals.

The detection and quantitation of antigenic substances and biological samples frequently ^' utilized immunoassay techniques. These

techniques are based upon the formation of the complex between the antigenic substance, e.g., gpl20, being assayed and an antibody or antibodies in which one or the other member of the complex may be detectably labeled. In the present invention, the immunoglobulin-like molecule or fusion protein may be labeled with any conventional label.

Thus, the hybrid fusion protein or immunoglobulin-like molecule of the invention can also be used in assay for HIV or SIV viral infection in a biological sample by contacting a sample, derived from an animal suspected of having an HIV or SIV infection, with the fusion protein or immunoglobulin-like molecule of the invention, and detecting whether a complex with gpl20, either alone or on the surface of an HIV-infected cell, has formed.

For example, a biological sample may be treated with nitro¬ cellulose, or other solid support which is capable of immobilizing cells, cell particles or soluble protein. The support may then be washed with suitable buffers followed by treatment with the fusion protein which may be detectably labeled. The solid phase support may then be washed with the buffer a second time to remove unbound fusion protein and the label on the fusion protein detected.

In carrying out the assay of the present invention on a sample containing gpl20, the process comprises: a) contacting a sample suspected containing gpl20 with a solid support to effect immobilization of gpl20, or cell which expresses gpl20 on its surface; b) contacting said solid support with the detectably labeled immunoglobulin-like molecule or fusion protein of the invention; c) incubating said detectably labeled immunoglobulin-like molecule with said support for a sufficient amount of time to allow the immunoglobulin-like molecule or fusion protein to bind to the immobilized gpl20 or cell which expresses gpl20 on its surface; d) separating the solid phase support from the incubation mixture obtained in step c); and

e) detecting the bound immunoglobulin-like molecule or fusion protein and thereby detecting and quantifying gpl20.

Alternatively, labeled immunoglobulin-like molecule (or fusion protein) -gpl20 complex in a sample may be separated from a reaction mixture by contacting the complex with an immobilized antibody or protein which is specific for an immunoglobulin or, e.g., protein A, protein G, anti-IgM or anti-IgG antibodies. Such anti-immunoglobulin antibodies may be monoclonal or polyclonal. The solid support may then be washed with suitable buffers to give an immobilized gpl20- labeled immunoglobulin-like molecule antibody complex. The label on the fusion protein may then be detected to give a measure of endogenous gpl20 and, thereby, the presence of HIV.

This aspect of the invention relates to a method for detecting HIV or SIV viral infection in a sample comprising

(a) contacting a sample suspected of containing gpl20 with a fusion protein or immunoglobulin-like molecule comprising CD4, or fragment thereof which binds to gpl20, and the Fc portion of an immunoglobulin chain,

(b) detecting whether a complex is formed.

The invention also relates to a method of detecting gpl20 in a sample, further comprising

(c) contacting the mixture obtained in step (a) with an Fc binding molecule, such as an antibody, protein A, or protein G, which is immobilized on a solid phase support and is specific for the hybrid fusion protein, to give a gpl20 fusion protein-immobilized antibody complex

(d) washing the solid phase support obtained in step (c) to remove unbound fusion protein,

(e) and detecting the label on the hybrid fusion protein. Of course, the specific concentrations of detectably labeled immunoglobulin-like molecule (or fusion protein) and gpl20, the temperature and time of incubation, as well as other assay conditions

ay be varied, depending on various factors including the concentra¬ tion of gpl20 in the sample, the nature of the sample, and the like. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.

Other such steps as washing, stirring, shaking, filtering and the like may be added to the assays as is customary or necessary for the particular situation.

One of the ways in which the immunoglobulin-like molecule or fusion protein of the present invention can be detectably labeled is by linking the same to an enzyme. This enzyme, in turn, when later exposed to its substrate, will react with the substrate in such a manner as to produce a chemical moiety which can be detected as, for example, by spectrophotometric, fluorometric or by visual means. Enzymes which can be used to detectably label the immunoglobulin-like molecule or fusion protein of the present invention include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta- V-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophos- phate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta- galactosidase, ribonuclease, urease, catalase, glucose-VI-phosphate dehydrogenase, glucoamylase and acetylcholine esterase.

The immunoglobulin-like molecule or fusion protein of the present invention may also be labeled with a radioactive isotope which can be determined by such means as the use of a gamma counter or a scintillation counter or by autoradiography. Isotopes which are particularly useful for the purpose of the present invention are: ³ H, 125 _I} 131^ 32p _} 35 _s , 14 _c> 51 _Cr , 36 _cl , 57 _c - ₅ 58 _Co> 59 _{Fe and} 75 _Se .

It is also possible to label the immunoglobulin-like molecule or fusion protein with a fluorescent compound. When the fluorescently labeled immunoglobulin-like molecule is exposed to light of the proper wave length, its presence can then be detected due to the fluorescence

of the dye. Among the most commonly used fluorescent labelling compounds are fluorescein isothiocyanate, rhodamine, phycoerytherin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.

The immunoglobulin-like molecule or fusion protein of the invention can also be detectably labeled using fluorescence emitting metals such as 152_ _U) or others of the lanthanide series. These metals can be attached to the immunoglobulin-like molecule or fusion protein using such metal chelating groups as diethylenetriaminepenta- acetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).

The immunoglobulin-like molecule or fusion protein of the present invention also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent- tagged immunoglobulin-like molecule or fusion protein is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

Likewise, a bioluminescent compound may be used to label the immunoglobulin-like molecule or fusion protein of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

Detection of the immunoglobulin-like molecule or fusion protein may be accomplished by a scintillation counter, for example, if the detectable label is a radioactive gamma emitter, or by a Fluorometer, for example, if the label is a fluorescent material. In the case of an enzyme label, the detection can be accomplished by colorimetric methods which employ a substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic

reaction of a substrate in comparison with similarly prepared standards.

The assay of the present invention is ideally suited for the preparation of a kit. Such a kit may comprise a carrier means being compartmentalized to receive in close confinement therewith one or more container means such as vials, tubes and the l ke, each of said container means comprising the separate elements of the immunoassay. For example, there may be a container means containing a solid phase support, and further container means containing the detectably labeled immunoglobulin-like molecule or fusion protein in solution. Further container means may contain standard solutions comprising serial dilutions of analytes such as gpl20 or fragments thereof to be detected. The standard solutions of these analytes may be used to prepare a standard curve with the concentration of gpl20 plotted on the abscissa and the detection signal on the ordinate. The results obtained from a sample containing gpl20 may be interpolated from such a plot to give the concentration of gpl20.

The immunoglobulin-like molecule or fusion protein of the present invention can also be used as a stain for tissue sections. For example, a labeled immunoglobulin-like molecule comprising CD4 or fragment thereof which binds to gpl20 may be contacted with a tissue section, e.g., a brain biopsy specimen. This section may then be washed and the label detected.

The following examples are illustrative, but not limiting the method and composition of the present invention. Other suitable modifications and adaptations which are obvious to this skill in the art are within the spirit and scope of this invention.

EXAMPLES

Example 1: Preparation of CD4-Ig cDNA Constructs

The extracellular portion of the CD4 molecule (See Madden, P.J., et al .. Cell 42:93-104 (1985)) was fused at three locations in a human IgGl heavy chain constant region gene by means of a synthetic splice donor linker molecule. To exploit the splice donor linker, a BamHI linker having the sequence CGCGGATCCGCG was first inserted at amino acid residue 395 of the CD4 precursor sequence (nucleotide residue 1295). A synthetic splice donor sequence

GATCCCGAGGGTGAGTACTA GGCTCCCACTCATGATTCGA bounded by BamHI and HindiII complementary ends was created and fused to the Hindlll site in the intron preceding the CHI domain, to the Espl site in the intron preceding the hinge domain, and to the Banl site preceding the CH2 domain of the IgGl genomic sequence. Assembly of the chimeric genes by ligation at the BamHI site afforded molecules in which either the variable (V) region, the V+CH1 regions, or the V, CHI and hinge regions were replaced by CD4. In the last case, the chimeric molecule is expected to form a monomer structure, while in the former, a dimeric molecule is expected.

On such genetic construct which contains the DNA sequence which encodes CD4 linked to human IgGl at the Hind3 site upstream of the CHI region (fusion protein CD4Hγl) is depicted in Table 1. The plasmid containing this genetic construct (pCD4Hγl) has been deposited in E. coli (MC1061/P3) at the American Type Culture Collection (ATCC) under the terms of the Budapest Treaty and given accession number 67611.

A second genetic construct which contains the DNA sequence which encodes CD4 linked to human IgGl at the Esp. site upstream of the hinge region (fusion protein CD4Eγl) is depicted in Table 2. The plasmid containing this genetic construct (pCD4Eγl) has been deposited in ξ__ coli (MC1061/P3) at the ATCC under the terms of the Budapest Treaty and given accession number 67610.

A third genetic construct which contains the DNA sequence which encodes CD4 linked to human IgM at the Mst2 site upstream of the CHI region (fusion protein CD4Mμ) is depicted in Table 3. The plasmid

containing this genetic construct (pCD4Mμ) has been deposited in . coli (MC1061/P3) at the ATCC under the terms of the Budapest Treaty and given accession number 67609.

A fourth genetic construct which contains the DNA sequence which encodes CD4 linked to human IgM at the Pst site upstream of the CH2 region (fusion protein CD4P/.) is depicted in Table 4. The plasmid containing this genetic construct (pCD4Pμ) has been deposited in JL. coli (MC1061/P3) at the ATCC under the terms of the Budapest Treaty and given accession number 67608.

A fifth genetic construct which contains the DNA sequence which encodes CD4 linked to human IgGl at the Banl site downstream from the hinge region (fusion protein CD4Bγl) is depicted in Table 5.

Two similar constructs were prepared from the human IgM heavy chain constant region by fusion with the introns upstream of the μ CHI and CH2 domains at an Mstll site and a Pstl site respectively. The fusions were made by joining the Pstl site of the CD4/IgGl construct fused at the Esp site in IgGl gene to the Mstll and Pst sites in the IgM gene. In the first instance, this was performed by treatment of the Pst end with T4 DNA Polymerase and the Mstll end with E. coli DNA Polymerase, followed by ligation; and in the second instance, by ligation alone.

Immunoprecipitation of the fusion proteins with a panel of monoclonal antibodies directed against CD4 epitopes showed that all of the epitopes were preserved. A specific high affinity association is demonstrated between the chimeric molecules and HIV envelope proteins expressed on the surface of cells transfected with an attenuated (reverse transcriptase deleted) proviral construct.

Table 1

S B

DHA S

RAU T

AE9 X 236 1

/

GCCTGTTTGAGAAGCAGCGGGCAAGAAAGACGCAAGCCCAGAGGCCCTGCCATTTCT GTG ______--_. ₊ __•_-_-_- ₊ — _-_-__- ₄ .—---— ._ ₊ ____---_- ₊ — _______ ₊ 60

CGGACAAACTCTTCGTCGCCCGπCTTTCTGCGTTCGGGTCTCCGGGACGGTAAAGA CAC

S HNC PCR AIF 211 / G CTGCCTCCCTCG ACAATGAACCGGG +. + + + ♦ ♦ 120

CCGAGTCCAGGGATGACCGAGTCCGGGGACGGAGGGAGCCGπCCGGTGTTACTTGG CCC

H I N F 1 GAGTCCCTTTTAGGCACπGCTTCTGGTGCTGCAACTGGCGCTCCTCCCAGCAGCCACTC + ♦ + •<•+ + + 180

CTCAGGGAAAATCCGTGAACGAAGACCACGACGTTGACCGCGAGGAGGGTCGTCGGT GAG

V P F R H L L L V L Q L A L L P A A T R -

R A S L A U 1 1

AGGGAAAGAAAGTGGTGCTGGGCAAAAAAGGGGATACAGTGGAACTGACCTGTACAG CTT + + + + «. ♦ 240

TCCCTTTCTTTCACCACGACCCGI 11111 CCCCTATGTCACCTTGACTGGACATGTCGAA

G K K V V L G K K G D T V E L T C T A S -

H M I

B B N

0 0 F

2 2 1

CCCAGAAGAAGAGCATACAATTCCACTGGAAAAACTCCAACCAGATAAAGATTCTGG GAA — — + ._♦__ .+_-_ +_.__ + ■ ♦ 300

GGGTCπCTTCTCGTATGTTAAGGTGACCTTTTTGAGGTTGGTCTATTTCTAAGACC Cπ

Q. K K S I Q F H W K N S N Q I K I L G N -

B S

NBS F AA

LAP 0 VU

AN1 K A9

422 1 26

/ / ATCAGGGCTCCTTCTTAACTAAAGGTCCATCCAAGCTGAATGATCGCGCTGACTCAAGAA + +___„„_=..+ — . .-_.+-- —+ — -+ 360

TAGTCCCGAGGAAGAATTGATTTCCAGGTAGGTTCGACTTACTAGCGCGACTGAGTT CTT

Q G S F L T K G P S K L N D R -A D S R R -

S

MANAS BVLUT 0AA9Y 22461

/

GAAGCCTTTGGGACCAAGGAAACTTCCCC ♦ + ■ — + + + + 420

CTTCGGAAACCCTGGTTCCTTTGAAGGGGGACTAGTAGTTCTTAGAATTCTATCπC TGA

S L W D Q G N F P L I I K N L K I E D S -

S

AMAM M

VNUN A

AL9L E 2161 1

//

CAGATACTTACATCTGTGAAGTGGAGGACCAGAAGGAGGAGGTGCAATTGCTAGTGT TCG + + + + + + 480

GTCTATGAATGTAGACACπCACCTCCTGGTCTTCCTCCTCCACGTTAACGATCACA AGC

D T Y I C E V E D Q K E E V L L V F G -

B

S S

P T

M Y

1 1

GATTGACTGCCAACTCTGACACCCACCTGCTTCAGGGGCAGAGCCTGACCCTGACCT TGG ♦ + ♦ ♦ + -+ 540

CTAACTGACGGTTGAGACTGTGGGTGGACGAAGTCCCCGTCTCGGACTGGGACTGGA ACC

L T A N S D T H L L Q G Q S L T L T L E -

B BS

BS SC D

AP TR D

Nl NF E

22 11 1

/ / AGAGCCCCCCTGGTAGTAGCCCCTCAGTGCAATGTAGGAGTCCAAGGGGTAAAAACATAC ____ _{+ +} __ _{+ + + +} 600

TCTCGGGGGGACCATCATCGGGGAGTCACGπACATCCTCAGGπCCCCATTTTTGT ATG

S P P G S S P S V Q C R S P R G K N I Q -

N BBH S B BS

ASP A BSSGSC S B N SC

LPV L APTIAR T A L TR

UBU U N1NACF X N A NF 122 1 221111 1 1 4 11

// / /// / AGGGGGGGAAGACCCTCTCCGTGTCTCAGCTGGAGCTCCAGGATAGTGGCACCTGGACAT ■ + + + + + + 660

TCCCCCCCTTCTGGGAGAGGCACAGAGTCGACCTCGAGGTCCTATCACCGTGGACCT GTA

G G K T L S V S Q L E L Q D S G T W T C -

N

NS M NM A

LP B HA L

AH 0 EE U

31 2 11 1

/ GCACTGTCTTGCAGAACCAGAAGAAGGTGGAGTTCAAAATAGACATCGTGGTGCTAGCTT ♦ ♦ + + + + 720

CGTGACAGAACGTCTTGGTCTTCTTCCACCTCAAGTTTTATCTGTAGCACCACGATC GAA

T V L Q N Q K K V E F K I D I V V L A F -

HS M M

AT N N

EU L L

31 1 1

/

TCCAGAAGGCCTCCAGCATAGTCTATAAGAAAGAGGGGGAACAGGTGGAGTTCTCCT TCC

AGGTCπCCGGAGGTCGTATCAGATAπCTTTCTCCCCCπGTCCACCTCAAGAGGA AGG

Q K A S S I V Y K K E G E Q V E F S F P -

A L U 1

CACTCGCCTTTACAGTTGAAAAGCTGACGGGCAGTGGCGAGCTGTGGTGGCAGGCGG AGA ♦ ._._ ₊ _- ₊ ___,_. . ₊ , _{+ +} 840

GTGAGCGGAAATGTCAACTTTTCGACTGCCCGTCACCGCTCGACACCACCGTCCGCC TCT L A F T V E K L T G S G E L W W Q A E R -

M

B 0 2

GGGCTTCCTCCTCCAAGTCTTGGATCACCTTTGACCTGAAGAACAAGGAAGTGTCTG TAA — _ . — ₊ — - ₊ — —_ ₊ __-___—_+ ._+_______—+ goo

CCCGAAGGAGGAGGπCAGAACCTAGTGGAAACTGGACTTCTTGπCCTTCACAGAC ATT

A S S S K S W I T F D L K N K E V S V K -

A H

L P

U H

1 1

AAC TCCAGATGGGCAAGAAGCTCCCGCTCCACCTCACCC + .— - + . + + + + 960

TTGCCCAATGGGTCCTGGGATTCGAGGTCTACCCGTTCTTCGAGGGCGAGGTGGAGT GGG

R V T Q D P K L Q M G K K L P L H L T L -

BSS

SCAHM

TRUAN

NF9EL

11631 / / TCTGGAAACCTCACCCTGGCCCTTGAAGCGA

961 . + + ♦—. + + + 1020

ACGGGGTCCGGAACGGAGTCATACGACCGAGACCTTTGGAGTGGGACCGGGAACTTC GCT

P Q A L P Q Y A G S G N L T L A L E A K -

S BS

F SC H D A

A TR P D L

N NF H E U

1 11 1 1 1

/

AAACAGGAAAGTTGCATCAGGAAGTGAACCTGGTGGTGATGAGAGCCACTCAGCTCC AGA

1021 + ♦ ^■ + + + + 1080

TTTGTCCTTTCAACGTAGTCCπCACπGGACCACCACTACTCTCGGTGAGTCGAGG TCT

T G K L H Q E V N L V V M R A T Q L Q K -

M

N L 1

AAAATTTGACCTGTGAGGTGTG TTGAAAC

1081 + -+ ♦ + + ♦ 1140

TTrTAAACTGGACACTCCACACCCCTGGGTGGAGGGGAπCGACTACGACTCGAACT TTG

^• N L T C E V W G P T S P K L M L S L K L -

M T H M DM

N A P N DS

L Q .A L ET

1 1 2 1 12

/ TGGAGAACAAGGAGGCAAAGGTCTCGAAGCGGGAGAAGCCGGTGTGGGTGCTGAACCCTG

1141 + + ♦ ♦ + ♦ 1200

ACCTCπGTTCCTCCGTTTCCAGAGCTTCGCCCTCπCGGCCACACCCACGACπGG GAC

E N K E A K V S K R E K P V V L N P E -

-30-

H PS H

F D M I A ADPA I

0 D A N V VRUU N K E E F A AAM9 F

1 1 3 1 1 2216 1

///

AGGCGGGGATGTGGCAGTGTCTGCTGAGTGACTCGGGACAGGTCCTGCTGGAATCCA ACA

1201 + — ^■ + — + -♦ + + 1260

- TCCGCCCCTACACCGTCACAGACGACTCACTGAGCCCTGTCCAGGACGACCTTAGGHGT

A G M W Q C L L S D S G Q V L L E S N I -

TCAAGGTTCTGCCCACA

1261 ^■ + + + >-+ + + 1320

AGTTCCAAGACGGGTGTACCAGGTGGGGCCACGTGCGCCTAGGGCTCCCACTCATGA TTC

K V L P T W S T P V H A D P E

BS

H H SC HS S M

P A TR AT T . N

H E NF EU Y L

1 3 11 31 1 1

/ / /

CTTTCTGGGGCAGGCCAGGCCTGACCπGGCTTTGGGGCAGGGAGGGGGCTAAGGTG AGG

1321 + ♦ + ♦ ^■ + + 1380

GAAAGACCCCGTCCGGTCCGGACTGGAACCGAAACCCCGTCCCTCCCCCGATTCCAC TCC

B A BH B P

BASHBHHNN P SG N BS F H

AHPHBAPAL A PI L AP L G

NAMAEEHRA L 1A A Nl M A

121112114 1 21 3 22 1 1

/ //// / /

CAGGTGGCGCCAGCAGGTGCACACCCAATGCCCATGAGCCCAGACACTGGACGCTGA ACC

1381 + ♦ + _* ♦ + 1440

GTCCACCGCGGTCGTCCACGTGTGGGTTACGGGTACTCGGGTCTGTGACCTGCGACT TGG

F BS S B SS B S FN

N M SC DNHA H S AAHNABSAC NS

U N TR RLAU H TNUUALPAPLR UP

D L NF AAE9 A NL99EAAN1UF DB

2 1 112436 111663412211 22

/ / / // / ^* /

TCGCGGACAGTTAAGAACCCAGGGGCCTCTGCGCCTGGGCCCAGCTCTGTCCCACAC CGC

1441 + ♦ ♦ ♦ ♦ ♦ 1500

AGCGCCTGTCAATTCπGGGTCCCCGGAGACGCGGACCCGGGTCGAGACAGGGTGTG GCG

A49.4.WP 122088

CCACCTCTCπ 1501 + + ♦ ,_+—- _{+ +} 560

CCAGTGTACCGTGGTGGAGAGAACGTCGGAGGTGGTTCeCGGGTAGCCAGAAGGGGG ACC

A S T K G P S V F P L A -

BH N M MSG

L N NPI

A L L1A

4 1 121

/ CACCCTCCTCCAAGAGCACCTCTGGGG GTCAAGGACT

1561 +- -♦ • + ■ + ♦ ♦ 1620

GTGGGAGGAGGTTCTCGTGGAGACCCCCGTGTCGCCGGGACCCGACGGACCAGTTCC TGA P S S K S T S G G T A A L G C L V K D Y -

NF A BH

H M T H D BANHBHN SN P SG

P A T P D AHAHBAL PU A PI

A E H H E NARAEEA B4 L 1A

23 1 1 1 1211124 2H 1 21

/ // /

ACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC ACA

1621 ♦ + ♦ ♦ + + 1680

TGAAGGGGCTTGGCCACTGCCACAGCACCπGAGTCCGCGGGACTGGTCGCCGCACG TGT

F P E P V T V S W N S G A L T S G V H T -

S

HNC PCR AIF 211

CCTTCCCGGCTGTCCTACAGT GTGC

1681 + + + + + ^♦ 1740

GGAAGGGCCGACAGGATGTCAGGAGTCCTGAGATGAGGGAGTCGTCGCACCACTGGC ACG F P A V L Q S S G L Y S L S S V V T V P -

B F B B H

SH N ASM B NSB I

PP U LTN A LPB A

1H 4 UXL N A1V E F

21 H 111 1421 2 1

/ CCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACA

1741 + + + ---+ ♦ + 1800

GGAGGTCGTCGAACCCGTGGGTCTGGATGTAGACGTTGCACTTAGTGTTCGGGTCG� �GT S S S L G T Q T Y I C N V N H K P S N T -

CCAAGGTGGACAAGAAAGTTGGTGAGAGGCCAGCACAGGGAGGGAGGGTGTCTGCTG GAA

1801 -—■ -+ —+ ■—+ •+ +■ -+ 1860

GGTTCCACCTGπCTTTCAACCACTCTCCGGTCGTGTCCCTCCCTCCCACAGACGAC Cπ

K V D K K V

BS F

BSC N

BTR U

VNF 4

111 H //

GCAG GACGCAT GCCCCAGTCCAGGGCAGCA

1861 +—■ + + ■♦ + ♦ 1920

CGTCCGAGTCGCGAGGACGGACCTGCGTAGGGCCGATACGTCGGGGTCAGGTCCCGT CGT s s

DBHMHNA HMNCN M MNDM

RBABPLU PNCRL N NLDB

AVE0HA9 ALIFA L LAEO

2132146 21114 1 1312

// // //

AGGCAGGCCCCGTCTGCCTCπCACCCGGAGCCTCTGCCCGCCCCACTCATGCTCAG GGA

1921 + + . + + + ♦ 1980

TCCGTCCGGGGCAGACGGAGAAGTGGGCCTCGGAGACGGGCGGGGTGAGTACGAGTC CCT

BS P

SC F

TR L

NF M

11 1

/ GAGGGTCTTCTGGCTTTTTCCCAGGCTCTGGGCAGGCACAG

1981 + ■—♦ + .-♦ + + 2040

CTCCCAGAAGACCGAAAAAGGGTCCGAGACCCGTCCGTGTCCGATCCACGGGGATTG GGT

S B B

DHA S DBS

RAU P DAP

AE9 M EN1

236 1 122

/ /

GGCCCTGCACACAAAGGGGCAGGTGCTGGGCTCAGACCTGCCAA

2041 ♦ ♦ —♦ + + . + 2100

CCGGGACGTGTGTTTCCCCGTCCACGACCCGAGTCTGGACGGTTCTCGGTATAGGCC CTC

DNPA D H

RLUU D A

AAM9 E E

2416 1 3

/ // GACCCTGCCCCTGACCTAAGCCCACCCCAAAGGCCAAACTCTCCACTCCCTCAGCTCGGA

2101 ♦ + + + + + 2160

CTGGGACGGGGACTGGAπCGGGTGGGGTTTCCGGTTTGAGAGGTGAGGGAGTCGAG CCT

H

I M MM

N N AB

F ^* L EO

1 1 32

/ CACCTTCTCTCCTCCCAGAπCCAGTAACTCCCAATCπCTCTCTG A AATCT 2161 -—- — ,-+-.—. + ._+ _{+ + +} 2220

GTGGAAGAGAGGAGGGTCTAAGGTCATTGAGGGTTAGAAGAGAGACGTCTCGGGTTT AGA

E P K S -

N BBS BS

M NS SSC SC HS M

A LP PTR TR AT N

E AH INF NF EU L

3 31 211 1131 1

/ / / / TGTGACAAAACTCACACATGCCCACCGTGCCCAGGTAAGCCAGCCCAGGCCTCGCCCTCC 2221 —-* + ♦ + + 2280

ACACTGTTTTGAGTGTGTACGGGTGGCACGGGTCCATTCGGTCGGGTCCGGAGCGGG AGG

C D K T H T C P P C P

B BS S S S

B N SM F . SC F DHNA HNC

A L PA 0 TR A RALU PCR

N A IE K NF N " AEA9 AIF 14 211 11 1 2346 211

/ / / AGCTCAAGGCGGGACAGGTGCCCTAGAGTAGCCTGCATCCAGGGACAGGCCCCAGCCGGG

2281 —+ ■ ♦ + ♦ + ⁺ 2340

TCGAGπCCGCCCTGTCCACGGGATCTCATCGGACGTAGGTCCCTGTCCGGGGTCGG CCC

BS S

A M M M D M SC M ANA M

F A B N D N TR B VLU B

L E O L E L NF 0 AA9 0

3 2 2 1 1 1 11 2 246 2

/ /

TGCTGACACGTCCACCTCCATCTCπCCTCAGCACCTGAACTCCTGGGGGGACCGTC AGT

2341 + + * ♦ + + 2400

ACGACTGTGCAGGTGGAGGTAGAGAAGGAGTCGTGGACTTGAGGACCCCCCTGGCAG TCA

A P E L L G G P S V -

M S AN M HMANNAC DM M

N T UL N PNVCLUR DS A

L Y 3A L ALAIA9F ET E

1 1 A3 1212146112 3

I I II I

CTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGT CAC

2401 — ♦ -*- ^■ ~+ +- • — + ■ + 2460

GAAGGAGAAGGGGGGTTTTGGGTTCCTGTGGGAGTACTAGAGGGCCTGGGGACTCCA GTG

F L F P P K P K D T L M I S R T P E V T -

N

NS M

LP A

AH E

31 2

/ ATGCGTGGTGGTGGACGTGAGCC CAAGTTCAACTGGTACGTGGA

2461 +— ♦ -+ + + ♦ 2520

TACGCACCACCACCTGCACTCGGTGCπCTGGGACTCCAGTTCAAGTTGACCATGCA CCT

C V V V D V S H E D P E V K F N Y V D -

R M

S A S

A E A

1 2 1

CGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCAC GTA 2521 —_♦- —+ _* ♦ + + 2580

GCCGCACCTCCACGTATTACGGTTCTGTTTCGGCGCCCTCCTCGTCATGTTGTCGTG CAT

G V E V H N A K T K P R E E Q Y N S T Y -

S BS

HNC HH M SC R

PCR GP N TR S

AIF AH L NF A

21111 1 11 1

/ /

CCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTA CAA

2581 +- — ■ + + ♦ ♦- + 2640

GGCCCACCAGTCGCAGGAGTGGCAGGACGTGGTCCTGACCGACTTACCGTTCCTCAT GTT

R V V S V L T V L H Q D W L N G K E Y K -

GTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGC CAA

2641 + + + ♦ 4 2700

CACGTTCCAGAGGπGTTTCGGGAGGGTCGGGGGTAGCTCTTTTGGTAGAGGTTTCG Gπ C K V S N K A L P A P I E K T I S K A K -

P S S S

ADNNPMA A H M N HHN BSAH

VRLLUNU U A N L APA GFUA

AAAAML9 9 E L A EAE LI9E

2244116 631 3 321 1163

//// / /

AGGTGGGACCCGTGGGGTGCGAGGGCCACATGGACAGAGGCCGGCTCGGCCCACCCT CTG

2701 + 4 .-♦ 2760

TCCACCCTGGGCACCCCACGCTCCCGGTGTACCTGTCTCCGGCCGAGCCGGGTGGGA GAC

N D M M S R D N A P S E L E B A 1 1 3 2 1 CCCTGAGAGTGACCGCTGTACCAACCTCTGTCCTACAGGGCAGCCCCGAGAACCACAGGT

2761 —— ♦ ♦- 4 ₊ 2820

GGGACTCTCACTGGCGACATGGTTGGAGACAGGATGTCCCGTCGGGGCTCTTGGTGT CCA

G Q P R E P Q V -

BS SC TR NF 11 / GTCAGCCTGACCTGCCT

2821 ^■ + ♦ ^■ -♦ + * + 2880

CATGTGGGACGGGGGTAGGGCCCTACTCGACTGGTTCTTGGTCCAGTCGGACTGGAC GGA

Y T L P P S R D E L T K N V S L T C L -

B F

S N H

P U P

M 4 A

1 H 2

GGTCAAAGGCπCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCC GGA 2881 + 4- 4 4 2940

CCAGTTTCCGAAGATAGGGTCGCTGTAGCGGCACCTCACCCTCTCGπACCCGTCGG CCT

V K G F Y P S D I A V E W E S N G Q P E -

B B V 1 GAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAG

2941 4 4 4 4 4 4 3000

CπGπGATGTTCTGGTGCGGAGGGCACGACCTGAGGCTGCCGAGGAAGAAGGAGAT GTC N N - K T T P P V L D S D G S F F L Y S -

S

NF M

LA N

AN L 31 1

/

CAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCπCTCATGCTCCGT GAT

3001 —— Φ —,__ ₊ ____ ₊ ,__ _{+ +} 3060

GTTCGAGTGGCACCTGπCTCGTCCACCGTCGTCCCCπGCAGAAGAGTACGAGGCA CTA

K L T V D K S R W Q Q G N V F S C S V M -

S

N N M M HNC

S L B N PCR

I A 0 L AIF

13 2 1 211

/ GCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATG

3061 -♦ —--♦--• ■— . . 4 3120

CGTACTCCGAGACGTGπGGTGATGTGCGTCTTCTCGGAGAGGGACAGAGGCCCATT TAC

H E A L H N H Y T Q K S L S L S P G K *

CXHHN

^" FMAPA

RAEAE

13321

/

AGTGCGACGGCCG

3121 4— 3133

TCACGCTGCCGGC

F N ^I ^ S B

N S B M H DHA S

U P B N G RAU T

4 B V L A AE9 X

H 2 1 1 1 236 1

/

GCCTGπTGAGAAGCAGCGGGCAAGAAAGACGCAAGCCCAGAGGCCCTGCCATπCT GTG

CGGACAAACTCπCGTCGCCCGπCTTTCTGCGπCGGGTCTCCGGGACGGTAAAGA CAC

S S

DHNA M HM HNC

RALU N AN PCR

AEA9 L EL AIF

2346 1 31 211 / / /

G CAGGCCCCTGCCTCCCTCGGCAAGGCCACAATGAACCGGG

61 4 4 • 4— 4 4 4 120

CCGAGTCCAGGGATGACCGAGTCCGGGGACGGAGGGAGCCGTTCCGGTGTTACTTGG CCC

H I N F 1 GAGTCCCTTTTAGGCACπGCTTCTGGTGCTGCAACTGGCGCTCCTCCCAGCAGCCACTC 21 . 4 4 4 4 4 4 180

CTCAGGGAAAATCCGTGAACGAAGACCACGACGTTGACCGCGAGGAGGGTCGTCGGT GAG V P F R H L L L V L Q L A L L P A A T Q -

AGGGAAAGAAAGTGGTGCTGGGCAAAAAAGGGGATACAGTGGAACTGACCTGTACAG Cπ 81 — — 4 4 4 4 4 4 24C

TCCCTTTCTTTCACCACGACCCGI MM ICCCCTATGTCACCTTGACTGGACATGTCGAA

G K K V V L G K K G D T V E L T C T A S -

H M I

B B N

0 0 F

2 2 1

CCCAGAAGAAGAGCATACAATTCCACTGGAAAAACTCCAACCAGATAAAGATTCTGG GAA 1 + + 300

GGGTCπcπCTCGTATGπAAGGTGACCmTTGAGGπGGTCTATπCTAAGACCC� �

^■' ,- K K S I Q F H W K N S N Q I K I L G N -

ATCAGG CCATCCAAGCTGAATGATCGCGCTGACTCAAGAA

301 4 4 4 4 4 4 360

TAGTCCCGAGGAAGAATTGATrTCCAGGTAGGπCGACπACTAGCGCGACTGAGπ cπ Q G S F L T K G P S K L N D R A D S R R -

S

MANAS BVLUT 0AA9Y 22461

/

GAAGCCTTTGGGACCAAGGAAACTTCCCC A A AAGAA

361 4 4 —-4 4 4 4 420

CTTCGGAAACCCTGGTTCCTTTGAAGGGGGACTAGTAGTTCπAGAAπCTATCπC TGA S L W D Q. G N F P L I I K N L K I E D S -

S

AMAM M

VNUN A

AL9L E 2161 1

CAGATACTTACATCTGTGAAGTGGAGGACCAGAAGGAGGAGGTGCAATTGCTAGTGT TCG 421 ~—-4 ♦ —+— —+— 4 480

GTCTATGAATGTAGACACπCACCTCCTGGTCTTCCTCCTCCACGTTAACGATCACA AGC D T Y I C E V E D R K E E V Q. L L V F G -

B

S S

^* P T

M Y

1 1

GAπGACTGCCAACTCTGACACCCACCTGCTTCAGGGGCAGAGCCTGACCCTGACCT TGG 81 4 4 4 4 4 -4 540

CTAACTGACGGTTGAGACTGTGGGTGGACGAAGTCCCCGTCTCGGA TGGGACTGGAACC L T A N S D T H L L Q G Q S L T L T L E -

B BS H

BS SC D M I S

AP TR D N N T

Nl NF E L F Y

22 11 1 1 1 1

/ / 41 A —GAGCCCCCC ₊ T.GGTAGTAGC ₊ C.C„CTCAGTGC ₊ AATGTAGGAG ₊ TCCAAGG -G_G_T ₊ AAAAACATAC _{+ 60} -

TCTCGGGGGGACCATCATCGGGGAGTCACGπACATCCTCAGGπCCCCATπTTGT ATG S P P G S S P S V Q C R S P R G K N I Q -

AGGGGGGGAAGACCCTCT - 1 4 4 4 4 4 4 660

TCCCCCCCπCTGGGAGAGGCACAGAGTCGACCTCGAGGTCCTATCACCGTGGACCT GTA G G K T L S V S L E L Q D S G T W T C -

N

NS M NM A

LP B HA L

AH 0 EE U

31 2 11 1

GCACTGTCπGCAGAACCAGAAGAAGGTGGAGTTCAAAATAGACATCGTGGTGCTAG CTT 1 — • — 4 — 4 • 4 4 '4 720

CGTGACAGAACGTCπGGTCπcπCCACCTCAAGTTTTATCTGTAGCACCACGATC GAA T V L Q N Q K K V E F K I D I V V L A F -

HS M

AT N N

EU L L

31 1 1

TCCAGAAGGCCTCCAGCATAGTCTATAAGAAAGAGGGGGAACAGGTGGAGTTCTCCT TCC + ♦ ^{♦ ♦ ♦ + 780}

AGGTCπCCGGAGGTCGTATCAGATAπCTTTCTCCCCCTTGTCCACCTCAAGAGGA AGG

Q. K A S S I V Y K K E G E Q V E F S F P -

A L U 1 CACTCGCCTTTACAGTTGAAAAGCTGACGGGCAGTGGCGAGCTGTGGTGGCAGGCGGAGA + + 4 ■ 4 + 840

■ GTGAGCGGAAATGTCAACTTTTCGACTGCCCGTCACCGCTCGACACCACCGTCCGCCTCT

L A F T V E K L T G S G E L W W Q A E R -

P S H M FM A M

P N LN U B

H L ML 3 0

1 1 11 A 2

GGGCπCCTCCTCCAAGTCπGGATCACCTTTGACCTGAAGAACAAGGAAGTGTCTG TAA 4 4 4 4 4 4 900

CCCGAAGGAGGAGGπCAGAACCTAGTGGAAACTGGACTTCTTGπCCTTCACAGAC Aπ A S S S K S W I T F D L K N K E V S V K -

B BS PS

SM SCADNPAD A A H

TA TRVRLUUD L L P

EE NFAAAM9E U U H

23 11224161 1 1 1

/ / / //

AACGGGTTACCCAGGACCCTAAGCTCCAGATGGGCAAGAAGCTCCCGCTCCACCTCA CCC

901 4 4 4 —-4 —4 4 960

TTGCCCAATGGGTCCTGGGATTCGAGGTCTACCCGπCTTCGAGGGCGAGGTGGAGT GGG R V T Q D P K L Q M G K K L P L H L T L -

BS BSS

M SC HS D M H SCAHM

N TR AT D N P TRUAN

L NF EU E L H NF9EL

1 11 31 1 1 1 11631

/ / / /

TGCCCCAGGCCTTGCCTCAGTATGCTGGCTCTGGAAACCTCACCCTGGCCCπGAAG CGA

961 + 4 4 — 4— ■ 4 4 1020

ACGGGGTCCGGAACGGAGTCATACGACCGAGACCTTTGGAGTGGGACCGGGAACTTC GCT P Q A L P Q Y A G S G N L T L A L E A K -

S BS

F SC H D A A TR P D L N NF H E U 1 11 1 1 1 / AAACAGGAAAGTTGCATCAGGAAGTGAACCTGGTGGTGATGAGAGCCACTCAGCTCCAGA 1021 ₊ _-_______ ₊ __„_ ₊ _. , ₊ __ , _{+ + 10} 80

TTTGTCCTTTCAACGTAGTCCπCACπGGACCACCACTACTCTCGGTGAGTCGAGG TCT T G K L H Q E V N L V V M R A T Q L Q K -

PS s

M ADNNPA DF AM DE A VRLLUU DA LN DS L

L AAAAM9 EN UL EP U

1 224416 11 11 11 1

///// / / /

AAAATTTGACCTGTGAGGTGTGGGGACCCACCTCCCCTAAGCTGATGCTGAGCTTGA AAC

1081 4 4 4 4 4 4 1140

TTTTAAACTGGACACTCCACACCCCTGGGTGGAGGGGATTCGACTACGACTCGAACT TTG N L T C E V W G P T S P K L M L S L K L -

M T H M DM

N A P N DS

L Q A L ET

1 1 2 1 12

/

TGGAGAACAAGGAGGCAAAGGTCTCGAAGCGGGAGAAGCCGGTGTGGGTGCTGAACC CTG

1141 -- 4 4 4 4— 4— 4 1200

ACCTCπGπCCTCCGTTTCCAGAGCπCGCCCTCπCGGCCACACCCACGACTTGG GAC E N K E A K V S K R E K P V W V L N P E -

H PS H

F D M I A ADPA I

0 D A N V VRUU N K E E F A AAM9 F

1 1 3 1 1 2216 1

///

AGGCGGGGATGTGGCAGTGTCTGCTGAGTGACTCGGGACAGGTCCTGCTGGAATCCA ACA

1201 + 4 4 4 4 4 1260

TCCGCCCCTACACCGTCACAGACGACTCACTGAGCCCTGTCCAGGACGACCTTAGGT TGT A G M W Q C L L S D S G Q V L L E S N I -

TCAAGGTTCTGCCCACA

1261 + + + + + + 1320

AGπCCAAGACGGGTGTACCAGGTGGGGCCACGTGCGCCTAGGGCTCCCACTCATGA TTC

K V L P T W S T P V H A D P E

SS F BS F

HHNCF -N BSC N

PGCRA U BTR U

AAIFN 4 VNF 4

21111 H 111 H // // GACGCATCCCGGCTATGCAGCCCCAGTCCAGGGCAGCAAGGC

1321 4 + 4 4 4 -4 1380

GAAGTCGCGAGGACGGACCTGCGTAGGGCCGATACGTCGGGGTCAGGTCCCGTCGTT CCG

S S

DBHVHNA HVNCN M MNDM

RBABPLU PNCRL N NLDB

AVE0HA9 A IFA L LAEO

2132146 21114 1 1312

// // //

AGGCCCCGTCTGCCTCπCACCCGGAGCCTCTGCCCGCCCCACTCATGCTCAGGGAG AGG

1381 — 4 4 4 4 4 4 1440

TCCGGGGCAGACGGAGAAGTGGGCCTCGGAGACGGGCGGGGTGAGTACGAGTCCCTC TCC

TGGGCAGGCACAGG AGGTGCCCCTAACCCAGG _{+ + +} * 1500

CAGAAGACCGAAAAAGGGTCCGAGACCCGTCCGTGTCCGATCCACGGGGATTGGGTC CGG

B B

S DBS

P DAP

M EN1

1 122

/

CTGCACACAAAGGGGCAGGTGCTGGGCTCAGACCTGCCA

1501 — 4- . --— -4 . +_.____—_♦___— ^, 1560

GACGTGTGTTTCCCCGTCCACGACCCGAGTCTGGACGGTTCTCGGTATAGGCCCTCC TGG

D H

D A

E E

1 3

CTGCCCCTGACCTAAGCCCACCCCAAAGGCCAAACTCTCCACTCCCTCAGCTCGGAC ACC

1561 4 4 4 4— 4 -4 1620

GACGGGGACTGGATTCGGGTGGGGTTTCCGGTTTGAGAGGTGAGGGAGTCGAGCCTG TGG

πCTCTCCTCCCAGATTCCAGTAACTCCCAATCπCTCTCTGCAGAGCCCAAATCTTGTG

1621 -- - 4 4 4 4 4 1680

AAGAGAGGAGGGTCTAAGGTCATTGAGGGTTAGAAGAGAGACGTCTCGGGTTTAGAA CAC

E P K S C D -

ACAAAACTCACACA T

168 4— — 4 4 ■ 4 4 1740

TGTTTTGAGTGTGTACGGGTGGCACGGGTCCATTCGGTCGGGTCCGGAGCGGGAGGT CGA K T H T C P P C P

BS S

GACACGTCCACCTCCATCTCπCCTCAGCAC TCAGTCπC

1801 — —— — ♦ 4 —4 -4 ——4 4 I860

CTGTGCAGGTGGAGGTAGAGAAGGAGTCGTGGACTTGAGGACCCCCCTGGCAGTCAG AAG

A P E L L G G P S V F -

CTCπCCCCCCAAAACCCAAGGACACCCTC

1861 . — 4- 4 4 4 4 4 1920

GAGAAGGGGGGTTTTGGGTTCCTGTGGGAGTACTAGAGGGCCTGGGGACTCCAGTGT ACG

L F P P K P K D T L M I S R T P E V T C -

M M DM M

A N DS B

E L ET 0

2 1 12 2

/

GTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGAC GGC 921 4 4 4 4 — 4 - — 4 1980

CACCACCACCTGCACTCGGTGCπCTGGGACTCCAGπCAAGTTGACCATGCACCTG CCG

V V V D V S H E D P E V K F N W Y V D G -

F FN

M N NSS

N U UPA

L 4 DBC

1 H 222

// GTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAG C C

1981 4 4 4- — 4 4 4 2040

CACCTCCACGTATTACGGTTCTGTTTCGGCGCCCTCCTCGTCATGπGTCGTGCATG GCC V E V H N A K T K P R E E Q Y N S T Y R -

HH M SC R

GP N TR S

AH L NF A

11 1 11 1

/

GTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAG TGC

2041 — 4 +—— 4—— 4— 4 .4 2100

CACCAGTCGCAGGAGTGGCAGGACGTGGTCCTGACCGACTTACCGTTCCTCATGTTC ACG V V S V L T V L H Q D W L N G K E Y K C -

AAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAA GGT

2101 — ♦-- +-—__—+_-__ ₊ .._4— 2160

TTCCAGAGGTTGTTTCGGGAGGGTCGGGGGTAGCTCTTTTGGTAGAGGTTTCGGπT CCA

K V S N K A L P A P I E K T I S K A K

P s s s

ADNNPMA A H M N HHN BSAH D

VRLLUNU U A N L APA GFUA D

AAAAML9 9 E L A EAE LI9E E

2244116 631 3 321 1163 1

//// / /

GGGACCCGTGGGGTGCGAGGGCCACATGGACAGAGGCCGGCTCGGCCCACCCTCTGC CCT

2161 — 4 ■ 4-— —4 4 4 4 2220

CCCTGGGCACCCCACGCTCCCGGTGTACCTGTCTCCGGCCGAGCCGGGTGGGAGACG GGA

R F S 0 A K 1 1 GAGAGTGACCGCTGTACCAACCTCTGTCCTACAGGGCAGCCCCGAGAACCACAGGTGTAC

2221 + + + ♦ + ^♦ 2280

CTCTCACTGGCGACATGGTTGGAGACAGGATGTCCCGTCGGGGCTCTTGGTGTCCAC ATG ^•

G Q _. P R E P Q V Y

ACCCTGCCCCCA GTCAGCCTGA

2281 4 4 4- - 2340

TGGGACGGGGGTAGGGCCCTACTCGACTGGπCTTGGTCCAGTCGGACTGGACGGAC CAG

T L P P S R D E L T K N Q V S L T C L V -

AAAGGCπCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG AAC

2341 — -4 4-— 4 4 4 2400

TTTCCGAAGATAGGGTCGCTGTAGCGGCACCTCACCCTCTCGπACCCGTCGGCCTC TTG

K G F Y P S D I A V E W E S N G Q P E N -

AACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCπcπCCTCTACAGC AAG

2401 — 4 4 4 4 4 2460 πGATGTTCTGGTGCGGAGGGCACGACCTGAGGCTGCCGAGGAAGAAGGAGATGTCGTTC

N Y K T T P P V L D S D G S F F . L Y S K -

B F S

S NM MBX NF M N

P UB ABM LA N S

M 40 EVN AN L I

1 H2 211 31 1 1

/

CTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATG CAT

2461 + 4 —4 4 4 4 2520

GAGTGGCACCTGπCTCGTCCACCGTCGTCCCCTTGCAGAAGAGTACGAGGCACTAC GTA

L T V D K S R W Q Q G N V F S C S V M H -

S N M M HNC

L B N PCR

A 0 L AIF

3 2 1 211

/

GAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA GTG

2521 ———-4— __—+__. __._+_________+ __ ₊ ____.__-_42580

CTCCGAGACGTGTTGGTGATGTGCGTCπCTCGGAGAGGGACAGAGGCCCATTTACT CAC

E A L H N H Y T Q K S L S L S P G K *

CXH FMA RAE 133

/ CGACGGCCG

2581 2589

GCTGCCGGC

Table 3

F N S B N S DHA S

RAU T

AE9 X 236 1

/

GCCTGTTTGAGAAGCAGCGGGCAAGAAAGACGCAAGCCCAGAGGCCCTGCCATTTCT GTG _{4 4 4 4} _ _{4 4} 60

CGGACAAACTCπCGTCGCCCGπCTTTCTGCGπCGGGTCTCCGGGACGGTAAAGA CAC

S DHNA RALU AEA9 2346 /

G CAGGCCCCTGCCTCCCTCG AA G 4 — 4 4 4 4 4 120

CCGAGTCCAGGGATGACCGAGTCCGGGGACGGAGGGAGCCGTTCCGGTGTTACTTGG CCC

H F

I B N HH

N B U HA

F V 4 AE

1 1 H 12

GAGTCCCTTTTAGGCACπGCTTCTGGTGCTGCAACTGGCGCTCCTCCCAGCAGCCA CTC 4 4 4 4 4 4 180

CTCAGGGAAAATCCGTGAACGAAGACCACGACGTTGACCGCGAGGAGGGTCGTCGGT GAG V P F R H L L L V L L A L L P A A T Q -

AGGGAAAGAAAGTGGTGCTGGGCAAAAAAGGGGATACAGTGGAACTGACCTGTACAG CTT 4 4 4 4 4 4 240

TCCCTTTCTTTCACCACGACCCGI I I 11 ICCCCTATGTCACCTTGACTGGACATGTCGAA G K K V V L G K K G D T V E L T C T A S -

H W W I

B B N

0 0 . F

2 2 1

CCCAGAAGAAGAGCATACAATTCCACTGGAAAAACTCCAACCAGATAAAGATTCTGG GAA — 4 4 4 4- . 4— — ■ + 300

GGGTCTTCTTCTCGTATGTTAAGGTGACCTTTTTGAGGTTGGTCTATTTCTAAGACC CTT

Q K K S I Q F H W K N S N Q I K I L G N -

B S S F H

NBS F AA A A N H I

LAP 0 VU L U U H N

AN1 K A9 U 3 D A F

422 1 26 1 A 2 1 1

/ /

ATCAGGGCTCCπCTTAACTAAAGGTCCATCCAAGCTGAATGATCGCGCTGACTCAA GAA + 4 4- 4 4 4 360

TAGTCCCGAGGAAGAATTGATπCCAGGTAGGπCGACTTACTAGCGCGACTGAGTT CTT

Q G S F L T K G P S K L N D R A D S R R -

S

MANAS

BVLUT

-0AA9Y

22461

/

GAAGCCTTTGGGACCAAGGAAACTTCCCC A C 4 4— 4 4 — 4 4 420

CπCGGAAACCCTGGπCCTTTGAAGGGGGACTAGTAGTTCπAGAAπCTATCπC TGA

S L D Q G N F P L I I K N L K I E D S -

S

M M AMAM M

B N VNUN A

0 L AL9L E

2 1 2161 1

//

CAGATACTTACATCTGTGAAGTGGAGGACCAGAAGGAGGAGGTGCAATTGCTAGTG� �CG 4 4 4 4 4 4 480

GTCTATGAATGTAGACACπCACCTCCTGGTCTTCCTCCTCCACGπAACGATCACA AGC D T Y I C E V E D Q K E E V Q L L V F G -

B

S S

P T

M Y ϊ 1

GAπGACTGCCAACTCTGACACCCACCTGCπCAGGGGCAGAGCCTGACCCTGACCT TGG

481 - 4 4 4 4 4 4 540

CTAACTGACGGTTGAGACTGTGGGTGGACGAAGTCCCCGTCTCGGACTGGGACTGGA ACC

L T A N S D T H L L Q G Q S L T L T L E -

B BS

BS SC D

AP TR D

Nl NF E

22 11 1

/ /

AGAGCCCCCCTGGTAGTAGCCCCTCAGTGCAATGTAGGAGTCCAAGGGGTAAAAACA TAC

541 _ + — . ₊ ___- ₊ 4 4 4 600

TCTCGGGGGGACCATCATCGGGGAGTCACGπACATCCTCAGGπCCCCATTTTTGT ATG S P P G S S P S V Q C R S P R G K N I Q -

AGGGGGGGAAGACCCTCT A CA GACAT 01 4 4 4 4 4 4 660

TCCCCCCCTTCTGGGAGAGGCACAGAGTCGACCTCGAGGTCCTATCACCGTGGACCT GTA

G G K T L S V S Q L E L Q D S G T W T C -

N

NS M NM A

LP B HA L

AH 0 EE U

31 2 11 1

/

GCACTGTCTTGCAGAACCAGAAGAAGGTGGAGTTCAAAATAGACATCGTGGTGCTAG CTT 61 4 4 4 4 4 4 720

CGTGACAGAACGTCπGGTCπCTTCCACCTCAAGTTTTATCTGTAGCACCACGATC GAA T V L Q N Q K K V E F K I D I V V L A F -

HS M M

AT N N

EU L L

31 1 1

TCCAGAAGGCCTCCAGCATAGTCTATAAGAAAGAGGGGGAACAGGTGGAGTTCTCCT TCC 4- 4 4 4 4 4 780

AGGTCπCCGGAGGTCGTATCAGATAπCTTTCTCCCCCπGTCCACCTCAAGAGGA AGG Q K A S S I V Y K K E G E Q V E F S F P -

A

L U 1 CACTCGCCTTTACAGTTGAAAAGCTGACGGGCAGTGGCGAGCTGTGGTGGCAGGCGGAGA 4 4 4 4 4 4 840

GTGAGCGGAAATGTCAACTTTTCGACTGCCCGTCACCGCTCGACACCACCGTCCGCC TCT L A F T V E K L T G S G E L tt W Q A E R -

M

B 0 2 GGGCπCCTCCTCCAAGTCTTGGATCACCTTTGACCTGAAGAACAAGGAAGTGTCTGTAA — 4 — 4 4 4— -4 4 900

CCCGAAGGAGGAGGTTCAGAACCTAGTGGAAACTGGACπCTTGTTCCTTCACAGAC ATT A S S S K S W I T F D L K N K E V S V K -

A H

L P

U H

1 1

AAC G TCCAGATGGGCAAGAAGCTCCCGCTCCACCTCACCC 4 4 4 4 4 4 960 πGCCCAATGGGTCCTGGGATTCGAGGTCTACCCGTTCTTCGAGGGCGAGGTGGAGTGGG

R V T Q. D P K L Q M G K K L P L H L T L -

BSS

SCAHM

TRUAN

NF9EL

11631 / /

T A GGCTCTGGAAACCTCACCCTGGCCCTTGAAGCGA 4 4 4 4 4 4 1020

ACGGGGTCCGGAACGGAGTCATACGACCGAGACCTTTGGAGTGGGACCGGGAACTTC GCT P Q A L P R Y A G S G N L T L A L E A K -

^■ -

S BS

F SC H D A

A TR P D L

N NF H E U

1 11 1 1 1

/

AAACAGGAAAGTTGCATCAGGAAGTGAACCTGGTGGTGATGAGAGCCACTCAGCTCC AGA

1021 + + 4 4 1080

TπGTCCTTTCAACGTAGTCCTTCACπGGACCACCACTACTCTCGGTGAGTCGAGG TCT

T G K L H Q E V N L V V M R A T Q L Q K -

PS S

M ADNNPA DF AM DE A

N VRLLUU DA LN DS L

L AAAAV9 EN UL EP U

1 224416 11 11 11 1

///// / / / AAAATTTGACCTGTGAGGTGTGGGGACCCACCTCCCCTAAGCTGATGCTGAGCTTGAAAC

1081 4— 4 4 4 4 4 1140

TTTTAAACTGGACACTCCACACCCCTGGGTGGAGGGGATTCGACTACGACTCGAACT TTG

N L T C E V W .G P T S P K L M L S L K L -

M T H M DM

N A P N DS

L Q A L ET

1 1 2 1 12

/

TGGAGAACAAGGAGGCAAAGGTCTCGAAGCGGGAGAAGCCGGTGTGGGTGCTGAACC CTG

1141 4 4 -—4 4 4 4 1200

ACCTCπGπCCTCCGTTTCCAGAGCπCGCCCTCπCGGCCACACCCACGACπGG GAC E N K E A K V S K R E K P V W V L N P E -

AGGCGGGGATGTGGCAGT A GG AG ATCCAACA

1201 4 4 4 4 4 4 1260

TCCGCCCCTACACCGTCACAGACGACTCACTGAGCCCTGTCCAGGACGACCTTAGGT TGT A G M Q C L L S D S G Q V L L E S N I -

TCAAGGTTCTGCCCACA

1261 — + — ■ •♦- — — +— — ♦ .—--. ^♦ —. ^< - — 1320

AGTTCCAAGACGGGTGTACCAGGTGGGGCCACGTGCGCCTAGGGCTCCCACTCATGA TTC

K V L P T W S T P V H A D P E

E BS SS F BS F

H CHH F SC HHNCF N BSC N

P OHA 0 TR PGCRA U BTR U

H 4AE K NF AAIFN 4 VNF 4

1 712 1 11 21111 H 111 H

I I II II

CTTCAGCGCTCCTGCCTGGACGCATCCCGGCTATGCAGCCCCAGTCCAGGGCAGCAA GGC 1321 —~. 4— — —-♦—_— ♦___—_.__*_—„___ ₊ 1380

GAAGTCGCGAGGACGGACCTGCGTAGGGCCGATACGTCGGGGTCAGGTCCCGTCGTT CCG

S S

DBHMHNA HMNCN VNDV

RBABPLU PNCR_ N NLDB

AVE0HA9 ALIFA L LAEO

2132146 21114 1 1312

// // //

AGGCCCCGTCTGCCTCπCACCCGGAGCCTCTGCCCGCCCCACTCATGCTCAGGGAG AGG

1381 4 4 4 4 4—- 4 1440

TCCGGGGCAGACGGAGAAGTGGGCCTCGGAGACGGGCGGGGTGAGTACGAGTCCCTC TCC

BS P

SC F

TR L

NF M

11 1

/ GTCTTCTGGCTTTTTCCCAGGCTCTGGGCAGGCACAG 1441 _{+ + + + + 4} 1500

CAGAAGACCGAAAAAGGGTCCGAGACCCGTCCGTGTCCGATCCACGGGGATTGGGTC CGG

B B

S DBS

P DAP

M EN1

1 122

/

CTGCACACAAAGGGGCAGGTGCTGGGCTCAGACCTGCCA

1501 4 4 4 4 4 4 1560

GACGTGTGTTTCCCCGTCCACGACCCGAGTCTGGACGGTTCTCGGTATAGGCCCTCC TGG

D H

D A

E E

1 3

CTGCCCCTGACCTAAGCCCACCCCAAAGGCCAAACTCTCCACTCCCTCAGCTCGGAC ACC

1561 + + 4 4 4 1620

GACGGGGACTGGAnCGGGTGGGGTTTCCGGTTTGAGAGGTGAGGGAGTCGAGCCTGT GG

L P L T * A H P K G T L H S L S S D T -

C P * P K P T P K A K L S T P S A R T P -

A P D L S P P Q R P N S P L P Q L G H L -

S DF F

DO A

EK N

11 1 / πCTCTCCTCCC AACTCCCAATCTTCTCTCTCAGGGAGTGCATCCGCCCC

1621 + + + + + + 1680

AAGAGAGGAGGGTCTAAGGTCATTGAGGGTTAGAAGAGAGAGTCCCTCACGTAGGCG GGG

C S A S A P -

P

M C

N 0 L R 1 1

AACCCTTTTCCCCCTCGTCTCCTGTGAGAATTCC ....

1681 4 1714

TTGGGAAAAGGGGGAGCAGAGGACACTCTTAAGG....

T L F P L V S C E N S ....

Table 4

F N S B

N S B M H DHA S

U P B N G RAU T

4 B . V L A AE9 X

H 2 1 1 1 236 1

/

GCCTGTTTGAGAAGCAGCGGGCAAGAAAGACGCAAGCCCAGAGGCCCTGCCATTTCT GTG • 4 . 4 4 4 4 4 60

CGGACAAACTCπCGTCGCCCGTTCTTTCTGCGπCGGGTCTCCGGGACGGTAAAGA CAC

B PS S S

DBS ADNPA D DHNA M HM HNC

DAP VRLUU D RALU N AN PCR

EN1 AAAM9 E AEA9 L EL AIF

12222416 1 2346 1 31 211

/ / // / / /

GGCTCAGGTCCCTACTGGCTCAGGCCCCTGCCTCCCTCGGCAAGGCCACAATGAACC GGG 4 4 4- — 4-- 4 ■♦ 120

CCGAGTCCAGGGATGACCGAGTCCGGGGACGGAGGGAGCCGTTCCGGTGTTACTTGG CCC

M N R G -

H F F

I B N HH N M D

N B U HA U N D

F V 4 AE 4 L E

1 1 H 12 H 1 1

GAGTCCCTTTTAGGCACTTGCTTCTGGTGCTGCAACTGGCGCTCCTCCCAGCAGCCA CTC 4 -4 +___-__ 4 , ₊ + 180

CTCAGGGAAAATCCGTGAACGAAGACCACGACGTTGACCGCGAGGAGGGTCGTCGGT GAG

V P F R H L L L V L Q L A L L P A A T Q -

R A S L A U 1 1 AGGGAAAGAAAGTGGTGCTGGGCAAAAAAGGGGATACAGTGGAACTGACCTGTACAGCTT 4 4 4 4 4 ₊ 240

TCCCTπCTTTCACCACGACCCGTTTTrTCCCCTATGTCACCTTGACTGGACATGTC GAA G K K V V L G K K G D T V E L T C T A S -

H M I

B B N

0 0 F

2 2 1

CCCAGAAGAAGAGCATACAATTCCACTGGAAAAACTCCAACCAGATAAAGATTCTGG GAA 4 4— 4 4 4 4 300

GGGTCπcπCTCGTATGπAAGGTGACCTTTTTGAGGπGGTCTATTTCTAAGACC Cπ

Q K K S I Q F H W K N S N Q I K I L G N -

S AA VU A9 26 /

ATCAGG A CTAAAGGTCCATCCAAGCTGAATGATCGCGCTGACTCAAGAA 4 — 4 4 4 4 4 360

TAGTCCCGAGGAAGAAπGATπCCAGGTAGGπCGACπACTAGCGCGACTGAGπ cπ Q G S F L T K G P S K L N D R A D S R R -

S

MANAS BVLUT 0AA9Y 22461

/

GAAGCCTTTGGGACCAAGGAAACπCCCCCTGA ATCAAGAA AAG 4 4 • 4 4 4 4 420

CπCGGAAACCCTGGπCCTTTGAAGGGGGACTAGTAGπcπAGAATTCTATCπC TGA

S L W D Q G N F P L I I K N L K I E D S -

S

M M AMAM M

B N VNUN A

0 L AL9L E

2 1 2161 1

//

CAGATACTTACATCTGTGAAGTGGAGGACCAGAAGGAGGAGGTGCAATTGCTAGTGT TCG 4 4 4 4 4 4 480

GTCTATGAATGTAGACACπCACCTCCTGGTCTTCCTCCTCCACGTTAACGATCACA AGC D T Y I C E V E D Q K E E V L L V F G -

B

S S

P T

M Y

1 1

GATTGACTGCCAACTCTGACACCCACCTGCTTCAGGGGCAGAGCCTGACCCTGACC� �GG + 4 ₄ + + 540

CTAACTGACGGTTGAGACTGTGGGTGGACGAAGTCCCCGTCTCGGACTGGGACTGGA ACC L T A N S D T H L L G Q S L T L T L E -

B BS

BS SC

AP TR

Nl NF

22 11

/ /

AGAGCCCCCCTGGTAGTAGCCCCTCAGTGCAATGTAGGAGTCCAAGGGGTAAAAACA TAC ^■■ 4 ■ ■ 4 ■ 4 4 4 4 600

TCTCGGGGGGACCATCATCGGGGAGTCACGTTACATCCTCAGGπCCCCATTTTTGT ATG S P P G S S P S V Q. C R S P R G K N I Q. -

AGGGGGGGAAGACCCTCT GACAT 4 4 4 4 4 4 660

TCCCCCCCTTCTGGGAGAGGCACAGAGTCGACCTCGAGGTCCTATCACCGTGGACCT GTA G G K T L S V S Q L E L Q D S G T W T C -

N

NS M NM A

LP B HA L

AH 0 EE U

31 2 11 1

GCACTGTCTTGCAGAACCAGAAGAAGGTGGAGπCAAAATAGACATCGTGGTGCTAG CTT 4 4 4 4 4 4 720

CGTGACAGAACGTCπGGTCπCTTCCACCTCAAGTTTTATCTGTAGCACCACGATC GAA T V L Q N Q K K V E F K I D I V V L A F -

HS M M

AT N N

EU L L

31 1 1

TCCAGAAGGCCTCCAGCATAGTCTATAAGAAAGAGGGGGAACAGGTGGAGTTCTCCT TCC ₄ 4 4 4 4 4 780

AGGTCπCCGGAGGTCGTATCAGATAπCTTTCTCCCCCTTGTCCACCTCAAGAGGA AGG ^' ( K A S S I V Y K K E G E Q. V E F S F P -

A A M

L L N

U U L

1 1 1

CACTCGCCTTTACAGTTGAAAAGCTGACGGGCAGTGGCGAGCTGTGGTGGCAGGCGG AGA 4 4 4 4 4 4 840

GTGAGCGGAAATGTCAACTTTTCGACTGCCCGTCACCGCTCGACACCACCGTCCGCC TCT L A F T V E K L T G S G E L W ft Q A E R -

M B 0 2 GGGCπCCTCCTCCAAGTCTTGGATCACCTTTGACCTGAAGAACAAGGAAGTGTCTGTAA 4 4 4 4 4 4 900

CCCGAAGGAGGAGGπCAGAACCTAGTGGAAACTGGACπcπGTTCCTTCACAGAC ATT A S S S K S W I T F D L K N K E V S V K -

A H

L P

U H

1 1

AAC TCCAGATGGGCAAGAAGCTCCCGCTCCACCTCACCC 4 4 4 4 4 4 960 πGCCCAATGGGTCCTGGGAπCGAGGTCTACCCGTTCTTCGAGGGCGAGGTGGAGTGGG R V T D P K L Q M G K K L P L H L T L -

BSS

SCAHM

TRUAN

NF9EL

11631 / /

T TCTGGAAACCTCACCCTGGCCCTTGAAGCGA 4 4 4 4 4 4 1020

ACGGGGTCCGGAACGGAGTCATACGACCGAGACCTTTGGAGTGGGACCGGGAACTTC GCT P Q. A L P Q Y A G S G N L T L A L E A K -

S BS

F SC H D A

A TR P D L

N NF H E U

1 11 1 1 1

/ AAACAGGAAAGTTGCATCAGGAAGTGAACCTGGTGGTGATGAGAGCCACTCAGCTCCAGA + + 4 1080

TTTGTCCTrTCAACGTAGTCCπCACπGGACCACCACTACTCTCGGTGAGTCGAGG TCT

T G K L H Q E V N L V V M R A T Q L Q K -

M N L 1

AAAATTTGACCTGTGAGGTGTG AAGC GAG 1081 -----4- +_________4_ . ₊ _.__«-___4— -— — 1140

TTTTAAACTGGACACTCCACACCCCTGGGTGGAGGGGATTCGACTACGACTCGAACT TTG

N L T C E V W G P T S P K L M L S L K L -

M T H M DM

N A P N DS

L Q A L ET

1 1 2 1 12

/ TGGAGAACAAGGAGGCAAAGGTCTCGAAGCGGGAGAAGCCGGTGTGGGTGCTGAACCCTG 1141 _{+ 4} „_+ _{4 4 + 12} oo

ACCTCTTGTTCCTCCGTTTCCAGAGCπCGCCCTCTTCGGCCACACCCACGACTTGG GAC E N K E A K V S K R E K P V W V L N P E -

H PS H

F D M I A ADPA I

0 D A N V VRUU N K E E F A AAM9 F

1 1 3 1 1 2216 1

///

AGGCGGGGATGTGGCAGTGTCTGCTGAGTGACTCGGGACAGGTCCTGCTGGAATCCA ACA

1201 4 4— 4 4 4 4 1260

TCCGCCCCTACACCGTCACAGACGACTCACTGAGCCCTGTCCAGGACGACCTTAGGT TGT A G M W C L L S D S G Q V L L E S N I -

S SA BHF BS H

ANA HNCP SGNMAANXA RSD I A

VLU PCRA PIUNMULHV SCD N L ^'

AA9 AIFL 1ADLH3A0A AAE D U

236 2111 21211A421 111 3 1

// II I I I I I

TCAAGGTTCTGCCCACATGGTCCACCCCGGTGCACGCGGATCCCGAGGGTGAGTACT AAG

2261 + + * ⁺ * 1320

AGπCCAAGACGGGTGTACCAGGTGGGGCCACGTGCGCCTAGGGCTCCCACTCATGA TTC

K V L P T W S T P V H A D P E

BS F

BSC N

BTR U

VNF 4

111 H // GACGCATC G A GCAGCCCCAGTCCAGGGCAGCAAGGC

1321 ^{+ + + +} * * ^13S0

GAAGTCGCGAGGACGGACCTGCGTAGGGCCGATACGTCGGGGTCAGGTCCCGTCGTT CCG

S S

DBHMHNA HMNCN M MNDM

RBABPLU PNCRL N NLDB

AVEDHA9 ALIFA L LAEG

2132146 21114 1 1312

// // //

AGGCCCCGTCTGCCTCπCACCCGGAGCCTCTGCCCGCCCCACTCATGCTCAGGGAG AGG

1381 + -4 4 4 4 1440

TCCGGGGCAGACGGAGAAGTGGGCCTCGGAGACGGGCGGGGTGAGTACGAGTCCCTC TCC

BS P

SC F

TR L

NF M

11 1

/

GTCπCTGGCTTTTTCCCAGGCTCTGGGCAGGCACAG

1441 4 4 _{+ +} 4 4 1500

CAGAAGACCGAAAAAGGGTCCGAGACCCGTCCGTGTCCGATCCACGGGGATTGGGTC CGG

B B

S DBS

P DAP

M EN1

1 122

/ CTGCACACAAAGGGGCAGGTGCTGGGCTCAGACCTGCCA

1501 + + 4~ — 1560

GACGTGTGTTTCCCCGTCCACGACCCGAGTCTGGACGGTTCTCGGTATAGGCCCTCC TGG

D H

D A

E E

1 3

CTGCCCCTGACCTAAGCCCACCCCAAAGGCCAAACTCTCCACTCCCTCAGCTCGGAC ACC

1561 + + 4 —4 1620

GACGGGGACTGGAπCGGGTGGGGTπCCGGTTTGAGAGGTGAGGGAGTCGAGCCTG TGG

H F

I M MM BP DE AN

N N AB BS DS LU

F L EO VT EP U4

1 1 32 11 11 1H

/ / / πCTCTCCTCCCAGAπCCAGTAACTCCCAATCπCTCTCTGCAGTGATTGCTGAGCTGC

1621 4 4 4- 4 4 4 1680

AAGAGAGGAGGGTCTAAGGTCATTGAGGGTTAGAAGAGAGACGTCACTAACGACTCG ACG

V I A E L P -

F M H M M N

B G N B U

0 A L 0 D

2 1 1 2 2

CTCCCAAAGTGAGCGTCTTCGTCCCACCCCGCGACGGCTTCTTCGGCAACCCCCGCA AGT

1681 > 4 .- 4— 4 + _— 4 1740

GAGGGTπCACTCGCAGAAGCAGGGTGGGGCGCTGCCGAAGAAGCCGTTGGGGGCGT TCA P K V S V F V P P R D G F F G N P R K S -

CCA CACGGGTTTCAGTC GC

1741 4 -4 • 4 . — — . 4 4 1800

GGTTCGAGTAGACGGTCCGGTGCCCAAAGTCAGGGGCCGTCTAAGTCCACAGGACCG ACG

K L I C Q A T G F S P R Q I Q V S W L R -

F B

NH S

UH P

DA M

21 1

/

GCGAGGGGAAGCAGGTGGGGTCTGGCGTCACCA A

1801 4 . 4 — 4 —4 4- 4 i860

CGCTCCCCTTCGTCCACCCCAGACCGCAGTGGTGCCTGGTCCACGTCCGACTCCGGT TTC

E G K Q. V G S G V T T D Q V Q A E A K E -

SS B B

AAHNABS SM H

UUALPAP TA P

99EAAN1 EE H

6634122 23 1

/ // /

^• AGTCTGGGCCCACGACCTACAAGGTGACCAGCACACTGACCATCAAAGAG....

1861 -4 4 4 4 1910

TCAGACCCGGGTGCTGGATGπCCACTGGTCGTGTGACTGGTAGTTTCTC....

S G P T T Y K V T S T L T I K E ....

Table 5

F N S B

N S B M H DHA S

U P B N G RAU T

4 B V L A AE9 X

H 2 1 1 1 236 1

/

GCCTGTTTGAGAAGCAGCGGGCAAGAAAGACGCAAGCCCAGAGGCCCTGCCATTTCT GTG __ ₄ _--- ₄ _________ ₄ -._ _ ₄ ..- - ₄ _ 4 60

CGGACAAACTCπCGTCGCCCGπCTTTCTGCGπCGGGTCTCCGGGACGGTAAAGA CAC

B PS S S

DBS ADNPA D DHNA M HM HNC

DAP VRLUU D RALU N AN PCR

EN1 AAAM9 E AEA9 L EL AIF

12222416 1 2346 1 31 211

/ / // / / /

GGCTCAGGTCCCTACTGGCTCAGGCCCCTGCCTCCCTCGGCAAGGCCACAATGAACC GGG 4 4 4 4 4 4 120

CCGAGTCCAGGGATGACCGAGTCCGGGGACGGAGGGAGCCGTTCCGGTGTTACTTGG CCC

M N R G -

H F F

I B N HH N M D

N B U HA U N D

F V 4 AE 4 L E

1 1 H 12 H 1 1

GAGTCCCTTTTAGGCACπGCπCTGGTGCTGCAACTGGCGCTCCTCCCAGCAGCCA CTC 4 4 4 4— —4 4 180

CTCAGGGAAAATCCGTGAACGAAGACCACGACGTTGACCGCGAGGAGGGTCGTCGGT GAG

V P F R H L L L V L L A L L P A A T -

R A S L A U 1 1 AGGGAAAGAAAGTGGTGCTGGGCAAAAAAGGGGATACAGTGGAACTGACCTGTACAGCTT 4 4 4 4 4 4 240

TCCCTTTCTTTCACCACGACCCGI I II 11 CCCCTATGTCACCTTGACTGGACATGTCGAA

G K K V V L G K K G D T V E L T C T A S -

H M M I

B B N

0 0 F

2 2 1

CCCAGAAGAAGAGCATACAATTCCACTGGAAAAACTCCAACCAGATAAAGATTCTGG GAA 4 4 4 4 4 4 300

GGGTCπcπCTCGTATGπAAGGTGACCTTTTTGAGGTTGGTCTATTTCTAAGACC CTT Q K K S I Q F H W K N S N Q I K I L G N -

ATCAGG CTCAAGAA

301 — — — 4 + — • 4- -- 4______ ^, 4______. 4 360

TAGTCCCGAGGAAGAATTGATTTCCAGGTAGGTTCGACTTACTAGCGCGACTGAGTT CTT Q G S F L T K G P S K L N D R A D S R R -

S

MANAS BVLUT 0AA9Y 22461

/ GAAGCCTTTGGGACCAAGGAAACTTCCCC 361 _____ ♦__-______♦__--__ — +__-_,___—+ ,___4 .—4 420

CTTCGGAAACCCTGGTTCCTTTGAAGGGGGACTAGTAGπcπAGAATTCTATCTTC TGA

S L W D Q G N F P L I I K N L K I E D S -

S

AMAM M

VNUN A

AL9L E 2161 1

//

CAGATACTTACATCTGTGAAGTGGAGGACCAGAAGGAGGAGGTGCAATTGCTAGTGT TCG

421 + + + + — + + 480

GTCTATGAATGTAGACACπCACCTCCTGGTCTTCCTCCTCCACGTTAACGATCACA AGC

D T Y I C E V E D Q K E E V Q L L V F G -

B

S S

P T

M Y

1 1

GATTGACTGCCAACTCTGACACCCACCTGCTTCAGGGGCAGAGCCTGACCCTGACCT TGG

481 4 4 4 4 4 4 540

CTAACTGACGGTTGAGACTGTGGGTGGACGAAGTCCCCGTCTCGGACTGGGACTGGA ACC L T A N S D T H L L G Q S L T L T L E -

B BS H

BS SC D M I S

AP TR D N N T

Nl NF E L F Y

22 11 1 1 1 1

/ / AGAGCCCCCCTGGTAGTAGCCCCTCAGTGCAATGTAGGAGTCCAAGGGGTAAAAACATAC 4 4 4 4 4 4 600

TCTCGGGGGGACCATCATCGGGGAGTCACGπACATCCTCAGGπCCCCATTTTTGT ATG S P P G S S P S V Q C R S P R G K N I Q -

N BBH S B BS

M MD ASP A BSSGSC S B N SC

B ND LPV L APTIAR T A L TR

0 LE UBU U N1NACF X N A NF

2 11 122 1 221111 1 1 4 11

// / /// /

AGGGGGGGAAGACCCTCTCCGTGTCTCAGCTGGAGCTCCAGGATAGTGGCACCTGGA CAT 4 4 4 4 4 4 660

TCCCCCCCπCTGGGAGAGGCACAGAGTCGACCTCGAGGTCCTATCACCGTGGACCT GTA G G K T L S V S Q L E L Q D S G T W T C -

N

NS M NM A

LP B HA L

AH 0 EE U

31 2 11 1

/

GCACTGTCTTGCAGAACCAGAAGAAGGTGGAGTTCAAAATAGACATCGTGGTGCTAG CTT 4 4 4 4 4 4 720

CGTGACAGAACGTCπGGTCπcπCCACCTCAAGTTTTATCTGTAGCACCACGATC GAA T V L Q N Q K K V E F K I D I V V L A F -

HS M M

AT N N

EU L L

31 1 1

TCCAGAAGGCCTCCAGCATAGTCTATAAGAAAGAGGGGGAACAGGTGGAGTTCTCCT TCC 4 4 4 4 780

AGGTCπCCGGAGGTCGTATCAGATAπCTTTCTCCCCCTTGTCCACCTCAAGAGGA AGG Q K A S S I V Y K K E G E Q V E F S F P -

A A M

L L N

U U L

1 1 1

CACTCGCCTTTACAGTTGAAAAGCTGACGGGCAGTGGCGAGCTGTGGTGGCAGGCGG AGA 4 4 4 4 4 4 840

GTGAGCGGAAATGTCAACTTTTCGACTGCCCGTCACCGCTCGACACCACCGTCCGCC TCT L A F T V E K L T G S G E L W W Q A E R -

M

B 0 2

GGGCTTCCTCCTCCAAGTCTTGGATCACCTTTGACCTGAAGAACAAGGAAGTGTCTG TAA — — .—— ₊ -- — .___._+_ __ +____.___,-_+_________+ 900

CCCGAAGGAGGAGGTTCAGAACCTAGTGGAAACTGGACTTCTTGπCCTTCACAGAC ATT

A S S S K S W I T F D L K N K E V S V K -

A H

L P

U H

1 1

AAC TCCAGATGGGCAAGAAGCTCCCGCTCCACCTCACCC - . +- —-._♦— __-- __+___ + 4 960

TTGCCCAATGGGTCCTGGGATTCGAGGTCTACCCGπcπCGAGGGCGAGGTGGAGT GGG

R V T Q. D P K L Q M G K K L P L H L T L -

BSS

SCAHM

TRUAN

NF9EL

11631 / /

T CCA G A A G GGCTCTGGAAACCTCACCCTGGCCCTTGAAGCGA 4 4 4 4 4 4 1020

ACGGGGTCCGGAACGGAGTCATACGACCGAGACCTTTGGAGTGGGACCGGGAACTTC GCT

P Q A L P Q Y A G S G N L T L A L E A K -

S BS

F SC H D A

A TR P D L

N NF H E U

1 11 1 1 1

/

AAACAGGAAAGTTGCATCAGGAAGTGAACCTGGTGGTGATGAGAGCCACTCAGCTCC AGA 4 4 4 4 4 4 1080

TTTGTCCTTTCAACGTAGTCCπCACTTGGACCACCACTACTCTCGGTGAGTCGAGG TCT T G K L H Q E V N L V V M R A T Q L Q K -

M N L 1

AAAATTTGACCTGTGAGGTGTG AGCTTGAAAC

1081 4 4 4 4 1140

TTTTAAACTGGACACTCCACACCCCTGGGTGGAGGGGATTCGACTACGACTCGAACT TTG

N L T C E V W G P T S P K L M L S L K L -

M N L 1

TGGAGAACAAGGAGGCAAAGGT

1141 4 4 4 —4 4 1200

ACCTCπGπCCTCCGTTTCCAGAGCπCGCCCTCπCGGCCACACCCACGACTTGG GAC

E N K E A K V S K R E K P V W V L N P E -

H PS H

F D • M I A . ADPA I

0 D A N V VRUU N K E E F A AAM9 F

1 1 3 1 1 2216 1

/// AGGCGGGGATGTGGCAGTGTCTGCTGAGTGACTCGGGACAGGTCCTGCTGGAATCCAACA

1201 4 4 4 4 4 — 1260

TCCGCCCCTACACCGTCACAGACGACTCACTGAGCCCTGTCCAGGACGACCTTAGGT TGT

A G M W Q C L L S D S G Q V L L E S N I -

S SA BHF BS B

ANA HNCP SGNMAANXA SH

VLU PCRA PIUNMULHV PP

AA9 AIFL 1ADLH3A0A 1H

236 2111 21211A421 21

// // / / / / TCAAGGTTCTGCCCACATGGTCCACCCCGGTGCACGCGGATCCCGAGGGTGAGTGTGCCC

1261 4 4 —4- 4 —4 4 1320

AGTTCCAAGACGGGTGTACCAGGTGGGGCCACGTGCGCCTAGGGCTCCCACTCACAC GGG

K V L P T W S T P V H A D P E

MF AO EK 11 / TAGAGTAGCCTGCATCCAGGGACAGGCCCCAGCCGGGTGCTGACACGTCCACCTCCATCT

1321 4—— . ————————*————♦— — 1380

ATCTCATCGGACGTAGGTCCCTGTCCGGGGTCGGCCCACGACTGTGCAGGTGGAGGT AGA

BS S

M D M SC M ANA M

N D N TR B VLU B

L E L NF 0 AA90

1 1 1 11 22462

/ /

CTTCCTCAGCACCTGAACTCCTGGGGGGACCGTCAGTCπCCTCTTCCCCCCAAAAC CCA

1381 + 4 4 4 4 4 144C

GAAGGA&TCGTGGACπGAGGACCCCCCTGGCAGTCAGAAGGAGAAGGGGGGTTTTG GGT A P E L L G G P S V F L F P P K P K -

M

A E 2 .

AGGACACCCTC TGGTGGTGGACGTGAGCC

1441 4 4 4—— 4 4- —-4 1500

TCCTGTGGGAGTACTAGAGGGCCTGGGGACTCCAGTGTACGCACCACCACCTGCACT CGG D T L M I S R T P E V T C V V V D V S H -

/

ACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATG CCA

1501 4 4 4 4 4 4 1560

TGCTTCTGGGACTCCAGTTCAAGTTGACCATGCACCTGCCGCACCTCCACGTATTAC GGT E D P. E V K F N W Y V D G V E V H N A K -

AGA AGCAG ACAACAG ACGTA GGGTGGTCAGCGTCCTCACCG

1561 4 4 4 4 4 4 1620

TCTGTTTCGGCGCCCTCCTCGTCATGTTGTCGTGCATGGCCCACCAGTCGCAGGAGT GGC T K P R E E Q Y N S T Y R V V S V L T V -

BS

M SC R

N TR S

L NF A

1 11 1

/

TCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAG CCC

1621 4 4 4 4 4 4 1680

AGGACGTGGTCCTGACCGACπACCGπCCTCATGπCACGπCCAGAGGπGTTTC GGG

L H Q D W L N G K E Y K C K V S N K A L -

P S S

M T ADNNPMA A

N A VRLLUNU U

L Q AAAAML9 9

1 1 2244116 6

//// /

TCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGTGGGACCCGTGGGGTGC GAG

1681 — 4 —4 4 4 4 4 1740

AGGGTCGGGGGTAGCTCTTTTGGTAGAGGTrTCGGTπCCACCCTGGGCACCCCACG CTC P A P I E K T I S K A K

S N

• H M N HHN BSAH D M M S R

A N L APA GFUA D N A P S

E L A EAE LI9E E L E B A

31 3 321 1163 1 1 3 2 1

/

GGCCACATGGACAGAGGCCGGCTCGGCCCACCCTCTGCCCTGAGAGTGACCGCTGTA CCA

1741 4— —4 4 4 4— 4 1800

CCGGTGTACCTGTCTCCGGCCGAGCCGGGTGGGAGACGGGACTCTCACTGGCGACAT GGT

F SS

M N A B R F AHNNCC

N U V B S O VPCCRR

L 4 A V A K AAIIFF

1 H 1 1 1 1 121111

//// ACCTCTGTCCTACAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGG

1801 4 4 4 4 4 4 i860

TGGAGACAGGATGTCCCGTCGGGGCTCTTGGTGTCCACATGTGGGACGGGGGTAGGG CCC G Q P R E P V Y T L P P S R D -

BS B SC S TR P NF M 11 1 / GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCG

1861 —■ + + 4 . — ₊ 4 1920

TACTCGACTGGTTCTTGGTCCAGTCGGACTGGACGGACCAGTTTCCGAAGATAGGGT CGC

E T K N Q V S G F Y P S D -

ACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGC CTC

1921 4 — 4 4 4 1980

TGTAGCGGCACCTCACCCTCTCGπACCCGTCGGCCTCπGTTGATGTTCTGGTGCG GAG

I A V E W E S N G Q. P E N N Y K T T P P -

CCGTGCTGGACTCCGACGGCTCCπCTTCCTCTACAGCAAGCTCACCGTGGACAAGA GCA

1981 4 4— • .+ 4— 4 4 2040

GGCACGACCTGAGGCTGCCGAGGAAGAAGGAGATGTCGTTCGAGTGGCACCTGTTCT CGT

V L D S D G S F F L Y S K L T V D K S R -

S

NF M N N

LA N S L

AN L I A 31 1 1 3

/

GGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACC ACT

2041 4 4 4 4 4 4 2100

CCACCGTCGTCCCCπGCAGAAGAGTACGAGGCACTACGTACTCCGAGACGTGTTGG TGA V M H E A L H N H Y -

CXH FMA RAE 133 / A GTAAATGAGTGCGACGGCCG

2101 4 4 4 -♦ 4 2150

TGTGCGTCTTCTCGGAGAGGGACAGAGGCCCATTTACTCACGCTGCCGGC

T Q K S L S L S P G K

Example 2: Preparation of the Fusion Proteins from Supernatants of COS Cells

COS cells grown in DME medium supplemented with 10% Calf Serum and gentamicin sulfate at 15 μg/ml were split into DME medium containing 10% NuSerum (Collaborative Research) and gentamicin to give 50% confluence the day before transfection. The next day, CsCl purified plasmid DNA was added to a final concentration of 0.1 to 2.0 μg/ml followed by DEAE Dextran to 400 μg/ml and chloroquine to 100 μM. After 4 hours at 37 ^β C, the medium was aspirated and a 10% solution of dimethyl sulfoxide in phosphate buffered saline was added for 2 minutes, aspirated, and replaced with DME/10% Calf Serum. 8 to 24 hours later, the cells were trypsinized and split 1:2.

For radiolabeling, the medium was aspirated 40 to 48 hours after transfection, the cells washed once with phosphate buffered saline, and DME medium lacking cysteine or methionine was added. 30 minutes later, ³⁵ S-labeled cysteine and methionine were added to final concentrations of 30-60 μci and 100-200 μci respectively, and the cells allowed to incorporate label for 8 to 24 more hours. The supernatants were recovered and examined by electrophoresis on 7.5% polyacrylamide gels following denaturation and reduction, or on 5% polyacr lamide following denaturation without reduction. The CD4Bγl protein gave the same molecular mass with or without reduction, while the CD4E-yl and CD4Hγl fusion proteins showed molecular masses without reduction of twice the mass observed with reduction, indicating that they formed dimer structures. The CD4 IgM fusion proteins formed large multimers beyond the resolution of the gel system without reduction, and monomers of the expected molecular mass with reduction.

Unlabeled proteins were prepared by allowing the cells to grow for 5 to 10 days post transfection in DME medium containing 5% NuSerum and gentamicin as above. The supernatants were harvested, centrifuged, and purified by batch adsorption to either protein A

trisacryl, protein A agarose, goat anti-human IgG antibody agarose, rabbit anti-human IgM antibody agarose, or monoclonal anti-CD4 antibody agarose. Antibody agarose conjugates were prepared by coupling purified antibodies to cyanogen bromide activated agarose according to the manufacturer's recommendations, and using an antibody concentration of 1 mg/ml. Following batch adsorption by shaking overnight on a rotary table, the beads were harvested by pouring into a sintered glass funnel and washed a few times on the funnel with phosphate buffered saline containing 1% Nonidet P40 detergent. The beads were removed from the funnel and poured into a small disposable plastic column (Quik-Sep QS-Q column, Isolab), washed with at least 20 column volumes of phosphate buffered saline containing 1% Nonidet P40, with 5 volumes of 0.15 M NaCl , 1 mM EDTA (pH 8.0), and eluted by the addition of either 0.1 M acetic acid, 0.1 M acetic acid containing 0.1 M NaCl, or 0.25 M glycine-HCl buffer, pH 2.5.

Example 3: Blockage of Svncvtium Formation by the Fusion Proteins

Purified or partially purified fusion proteins were added to HPB- ALL cells infected 12 hours previously with a vaccinia virus recombinant encoding HIV envelope protein. After incubation for 6-8 more hours, the cells were washed with phosphate buffered saline, fixed with formaldehyde, and photographed. All of the full-length CD4 immunoglobulin fusion proteins showed inhibition of syncytium formation at a concentration of 20 μg/ml with the exception of the 4H I protein, which was tested only at 5 μg/ml and showed partial inhibition of syncytium formation under the same conditions.

Example 4: Chromium Release Cytolysis Assay

The purified fusion proteins were examined for ability to fix complement in a chromium release assay using vaccinia virus infected cells as a model system. Na alwa (B cell) or HPB-ALL (T cell) lines

were infected with vaccinia virus encoding HIV envelope protein, and 18 hours later were radiolabeled by incubation in 1 ci/m sodium 5*chromate in phosphate buffered saline for 1 hour at 37°. The labeled cells were centrifuged to remove the unincorporated chromate, and incubated in microtiter wells with serial dilutions of the CD4 immunoglobulin fusion proteins and rabbit complement at a final concentration of 40%. After 1 hour at 37', the cells were mixed well, centrifuged, and the supernatants counted in a gamma-ray counter. No specific release could be convincingly documented.

Example 5: Binding of the CD4EΎ1 Protein to Fc Receptors

Purified CD4Eγl fusion protein was tested for its ability to displace radiolabeled human IgGl from human Fc receptors expressed on COS cells in culture. The IgGl was radiolabeled with sodium ¹²⁵ iodide using 1 mci of iodide, 100 μg of IgGl, and two idobeads (Pierce). The labeled protein was separated from unincorporated counts by passage over a Sephadex G25 column equilibrated with phosphate buffered saline containing 0.5 mM EDTA and 5% nonfat milk. Serial dilutions of the CD4Eγl fusion protein or unlabeled IgGl were prepared and mixed with a constant amount of radiolabeled IgGl tracer. After incubation with COS cells bearing the FcRI and RcRII receptors at 4 ^β C for at least 45 minutes in a volume of 20 μl , 200 μl of a 3:2 mixture of dibutyl to dioctyl phthalates were added, and the cells separated from the unbound label by centrifugation in a microcentrifuge for 15 to 30 seconds. The tubes were cut with scissors, and the cell pellets counted in a gamma-ray counter. The affinity of the CD4Eγl protein for receptors was measured in parallel with the affinity of the authentic IgGl protein, and was found to be the same, within experimental error.

Example 6: Stable Expression of the Fusion Construct PCD4EΎ! in Baby Hamster Kidney Cells

Twenty-four hours before transfection, 0.5 x 10^ baby hamster kidney cells (BHK; ATCC CCL10) were seeded in a 25 cm ² culture flask in Dulbecco's modified Eagle's medium (DMEM) containing 10% of fetal calf serum (FCS). The cells were cotransfected with a mixture of the plas ids pCD4E-yl (20 μg), pSV2dhfr (5 μg; Lee et al.. Nature 294:228- 232 (1981)) and pRMH140 (5 μg, Hudziak et al.. Cell 31:137-146 (1982)) according to a modified calcium phosphate transfection technique as described in Zettlmeissl et al . (Behring Inst. Res. Comm. 82:26-34 (1988)). 72 h post-transfection, cells were split 1:3 to 1:4 (60 mm culture dishes) and resistant colonies were selected in DMEM medium containing 10% FCS, 400 μg/ml G418 (Geneticin, Gibco) and 1 μM methotrexate (selection medium). The medium was changed twice a week. The resistant colonies (40-100/transfection) appeared 10-15 day post- transfection and were further propagated either as a mixture of clones (i.e., BHK-MK1) or as individually isolated clones. For the determination of the relative expression levels, clone mixtures or individual clones were grown to confluency in T25 culture flasks, washed twice with protein-free DMEM medium, and incubated for 24 h with 5 ml protein-free DMEM medium. These media were collected and subjected to a human IgG specific ELISA in order to determine the relative expression levels of the CD4-IgGl fusion protein CD4Eγl. For further analysis an individual clone (BHK-UC3) was chosen due to its high relative expression levels.

Example 7: Detection of the CD4EΎ1 Protein in Culture Supernatants

For 25s methionine labeling of cells, the clone BHK-UC3 and untransfected BHK cells (control) were grown to confluency in T25 culture flasks and subsequently incubated for two hours in HamF12 medium without methionine. Labeling was achieved by incubating 24 h in 2.5 ml of the same medium containing 100 μCi ^5$ methionine (1070 Ci/mmole, Amersham) . For the preparation of cell lysates, the labeled

cells were harvested in 1 ml of phosphate buffered saline, pH 7.2 (PBS) and lysed by repetitive freezing and thawing. Cleared lysates (after centrifugation 20000 rpm, 20 min) and culture supernatants were incubated with Protein A-Sepharose (Pharmacia) and the bound material was analyzed on a 10% SDS-Protein A-Sepharose (Pharmacia) and the bound material was analyzed on a 10% SDS-gel according to Laemmli (Nature 227:680-685 (1970)), which was subsequently autoradiographed. A specific band of about 80 KDa can be detected only in the supernatant of clone BHK-UC3, which is absent in the lysate of clone BHK-UC3 and in the respective controls.

Example 8: Purification of the Protein CD4EΎ1 from Culture Supernatants

In order to demonstrate that the fusion protein coded by the plasmid pCD4Eγl can be obtained in high quantities, the clone BHK-UC3 was grown in 1750 cm ² roller bottles in selection medium (500 ml). Confluent monolayers were ^" washed twice with protein-free DMEM medium (200 ml) and further incubated for 48 h with protein-free DMEM medium (500 ml). The conditioned culture supernatants (1-2 1) and respective supernatants from untransfected BHK cells were cleared by centrifugation (9000 rpm, 30 min) and microfiltered through a 0.45 μ membrane (Nalgene). After addition of 1% (v/v) of 1.9 M Tris-HCl buffer, pH 8.6, the conditioned medium was absorbed to a Protein A- Sepharose column equilibrated with 50 mM Tris-HCl pH 8.6 buffer containing 150 mM NaCl (4 ^β C). The loaded column was washed with 10 column volumes of equilibration buffer. Elution of the CD4-IgGl fusion protein CD4Eγl was achieved with 0.1 M sodium citrate buffer, pH 3, followed by immediate neutralization of the column efflux to pf-f 8 by Tris-base. The peak fractions were pooled, and the pool was analyzed on a Coomassie blue stained SDS-gel resulting in a band of the expected size (80 KDa), and which reacted with a polyclonal anti- hu an IgG heavy chain antibody and a mouse monoclonal anti-CD4

antibody (BMA040, Behringwerke) in Western Blots. The yields of purified fusion proteins obtained by the given procedure is 5-18 mg/24 h/1 culture supernatant. The respective value for a BHK clone mixture (about 80 resistant clones; BHK-MK1) as described above was 2-3 mg/24 h/1.

Example 9: Physical and Biological Characterization of the CD4E-yl Fusion Protein

As proven by SDS-electrophoresis on 10-15% gradient gels (Phast- System, Pharmacia) under non-reductive conditions, the CD4E I fusion protein migrates at the position of a homodimer (about 160 KDa) like a non-reduced mouse monoclonal antibody. This result is supported by analytical equilibrium ultracentrifugation, where the fusion protein behaves as a homogeneous dimeric molecule of about 150 KDa. The absorbance coefficient of the protein was determined as A28O ⁼ -& cm ² /mg using the quantitative protein determination according to Bradford (Anal. Biochem. 72:248-254 (1976)).

The CD4Eγl-fusion protein shows specific complex formation with a solubilized Jgal-gpl20 fusion protein (pMB1790; Broker et al., Behrinq Inst. Res. Commun. 82:338-348 (1988)) expressed in E. coli. In this protein (110 KDa), a major part of the HIV gpl20 protein (Va^g- Trp64δ) is fused to J-galactosidase (amino acids 1-375). In a control experiment a 67-KDa øgal-HIV 3'orf fusion protein ( gal1-375; 3'orf Prol4-Aspl23) showed no complex formation. In these experiments, the CD4Eγl-protein was incubated with the respective fusion protein in molar rations of about 5:1. The complex was isolated by binding to Protein A-Sepharose and the Protein A-Sepharose bound proteins- together with relevant controls--were analyzed on 10-15% gradient SDS- gels (Phast-System, Pharmacia).

The CD4Eγl fusion protein binds to the surface of HIV (HIV1/HTLV- IIIB) infected cultured T4-lymphocytes as determined by direct immunofluorescence with fluorescein-isothiocyanate (FITC) labeled

CD4Eγl protein. It blocks syncytia formation in cultured T4- lymphocytes upon HIV infection (0.25 TCID/cell) at a concentration of 10 μg/ml. Furthermore, HIV-infected cultured T4-lymphocytes (subclone of cell line H9) are selectively killed upon incubation with CD4Eγl in the presence or absence of complement: To a highly (>50%) HIV infected culture of T4-lymphocytes (10^ cells/ml) 50, 10 or 1 μg/ml CD4Eγl fusion protein was added in the presence or absence of guinea pig complement. Cells were observed for specific killing by the fusion protein, which is defined by the percentage of killed cells after 3 days in relation to viable cells in the culture at the beginning of the experiment corrected by the values for unspecific killing observed in control cultures, lacking the CD4E-/1 fusion protein (Table 5, Experiment I). Surprisingly, addition of CD4Eγl protein to the infected T4 cells in the absence of complement resulted in similar specific killing rates as in the presence of complement (Table 5, Experiment II). This result demonstrates a complement independent cytolytic effect of CD4Eγl on HIV infected T-lymphocytes in culture.

Table 5 o. Experiment Assay System Specific Killing (%)

I non-infected T4-cells 0.7 + 50 μg/ml CD4Eγl + Compl . infected T4-cells 35.1

+ 50 μg/ml CD4E7I + Compl . infected T4-cells 25.1

+ 10 μg/ml CD4Eγl + Compl . infected T4-cells 25

+ 1 μg/ml CD4Eγl + Compl .

II infected T4-cells 49.9 + 10 μg/ml CD4E7I + Compl . infected T4-cells 69.4

+ 10 μg/ml CD4Eγl + Compl .

Having now fully described this invention, it will be appreciated by those skilled in the art that the same can be performed with any wide range of equivalent parameters of composition, conditions, and methods of preparing such fusion proteins without departing from the spirit or scope of the invention or any embodiment thereof.

International Application No: PCT/

Form PCT/RO/134 (January IM1)

International Application No: PCT/

r_

=3 C —_ _

International Application No: PCT/

Form PCT/RO/134 (Janusry IMt)

International Application No: PCT/

Form PCT/RO/1M (Jsnusry 1M1)